Source Name	Characteristics[organism]	Characteristics[organism part]	Characteristics[pool]	Characteristics[age]	Characteristics[ancestry category]	Characteristics[cell type]	characteristics[developmental stage]	Characteristics[compound]	Characteristics[phenotype]	Characteristics[depletion]	Characteristics[cell line]	Characteristics[sex]	Characteristics[disease]	Characteristics[individual]	Material Type	assay name	Technology Type	comment[fraction identifier]	comment[label]	comment[data file]	comment[file uri]	comment[instrument]	comment[cleavage agent details]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[dissociation method]	comment[collision energy]	comment[fragment mass tolerance]	comment[precursor mass tolerance]	Factor value[compound]	Factor value[phenotype]
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 1	proteomic profiling by mass spectrometry	1	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 1	proteomic profiling by mass spectrometry	1	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 1	proteomic profiling by mass spectrometry	1	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 1	proteomic profiling by mass spectrometry	1	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 1	proteomic profiling by mass spectrometry	1	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 1	proteomic profiling by mass spectrometry	1	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 1	proteomic profiling by mass spectrometry	1	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 1	proteomic profiling by mass spectrometry	1	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 1	proteomic profiling by mass spectrometry	1	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 1	proteomic profiling by mass spectrometry	1	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 2	proteomic profiling by mass spectrometry	2	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 2	proteomic profiling by mass spectrometry	2	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 2	proteomic profiling by mass spectrometry	2	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 2	proteomic profiling by mass spectrometry	2	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 2	proteomic profiling by mass spectrometry	2	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 2	proteomic profiling by mass spectrometry	2	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 2	proteomic profiling by mass spectrometry	2	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 2	proteomic profiling by mass spectrometry	2	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 2	proteomic profiling by mass spectrometry	2	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 2	proteomic profiling by mass spectrometry	2	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 3	proteomic profiling by mass spectrometry	3	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 3	proteomic profiling by mass spectrometry	3	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 3	proteomic profiling by mass spectrometry	3	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 3	proteomic profiling by mass spectrometry	3	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 3	proteomic profiling by mass spectrometry	3	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 3	proteomic profiling by mass spectrometry	3	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 3	proteomic profiling by mass spectrometry	3	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 3	proteomic profiling by mass spectrometry	3	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 3	proteomic profiling by mass spectrometry	3	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 3	proteomic profiling by mass spectrometry	3	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 4	proteomic profiling by mass spectrometry	4	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 4	proteomic profiling by mass spectrometry	4	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 4	proteomic profiling by mass spectrometry	4	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 4	proteomic profiling by mass spectrometry	4	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 4	proteomic profiling by mass spectrometry	4	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 4	proteomic profiling by mass spectrometry	4	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 4	proteomic profiling by mass spectrometry	4	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 4	proteomic profiling by mass spectrometry	4	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 4	proteomic profiling by mass spectrometry	4	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 4	proteomic profiling by mass spectrometry	4	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 5	proteomic profiling by mass spectrometry	5	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 5	proteomic profiling by mass spectrometry	5	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 5	proteomic profiling by mass spectrometry	5	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 5	proteomic profiling by mass spectrometry	5	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 5	proteomic profiling by mass spectrometry	5	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 5	proteomic profiling by mass spectrometry	5	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 5	proteomic profiling by mass spectrometry	5	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 5	proteomic profiling by mass spectrometry	5	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 5	proteomic profiling by mass spectrometry	5	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 5	proteomic profiling by mass spectrometry	5	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 6	proteomic profiling by mass spectrometry	6	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 6	proteomic profiling by mass spectrometry	6	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 6	proteomic profiling by mass spectrometry	6	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 6	proteomic profiling by mass spectrometry	6	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 6	proteomic profiling by mass spectrometry	6	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 6	proteomic profiling by mass spectrometry	6	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 6	proteomic profiling by mass spectrometry	6	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 6	proteomic profiling by mass spectrometry	6	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 6	proteomic profiling by mass spectrometry	6	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 6	proteomic profiling by mass spectrometry	6	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 7	proteomic profiling by mass spectrometry	7	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 7	proteomic profiling by mass spectrometry	7	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 7	proteomic profiling by mass spectrometry	7	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 7	proteomic profiling by mass spectrometry	7	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 7	proteomic profiling by mass spectrometry	7	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 7	proteomic profiling by mass spectrometry	7	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 7	proteomic profiling by mass spectrometry	7	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 7	proteomic profiling by mass spectrometry	7	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 7	proteomic profiling by mass spectrometry	7	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 7	proteomic profiling by mass spectrometry	7	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 8	proteomic profiling by mass spectrometry	8	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 8	proteomic profiling by mass spectrometry	8	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 8	proteomic profiling by mass spectrometry	8	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 8	proteomic profiling by mass spectrometry	8	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 8	proteomic profiling by mass spectrometry	8	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 8	proteomic profiling by mass spectrometry	8	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 8	proteomic profiling by mass spectrometry	8	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 8	proteomic profiling by mass spectrometry	8	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 8	proteomic profiling by mass spectrometry	8	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 8	proteomic profiling by mass spectrometry	8	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 9	proteomic profiling by mass spectrometry	9	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 9	proteomic profiling by mass spectrometry	9	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 9	proteomic profiling by mass spectrometry	9	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 9	proteomic profiling by mass spectrometry	9	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 9	proteomic profiling by mass spectrometry	9	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 9	proteomic profiling by mass spectrometry	9	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 9	proteomic profiling by mass spectrometry	9	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 9	proteomic profiling by mass spectrometry	9	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 9	proteomic profiling by mass spectrometry	9	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 9	proteomic profiling by mass spectrometry	9	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 10	proteomic profiling by mass spectrometry	10	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 10	proteomic profiling by mass spectrometry	10	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 10	proteomic profiling by mass spectrometry	10	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 10	proteomic profiling by mass spectrometry	10	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 10	proteomic profiling by mass spectrometry	10	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 10	proteomic profiling by mass spectrometry	10	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 10	proteomic profiling by mass spectrometry	10	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 10	proteomic profiling by mass spectrometry	10	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 10	proteomic profiling by mass spectrometry	10	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 10	proteomic profiling by mass spectrometry	10	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 11	proteomic profiling by mass spectrometry	11	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 11	proteomic profiling by mass spectrometry	11	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 11	proteomic profiling by mass spectrometry	11	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 11	proteomic profiling by mass spectrometry	11	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 11	proteomic profiling by mass spectrometry	11	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 11	proteomic profiling by mass spectrometry	11	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 11	proteomic profiling by mass spectrometry	11	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 11	proteomic profiling by mass spectrometry	11	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 11	proteomic profiling by mass spectrometry	11	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 11	proteomic profiling by mass spectrometry	11	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 12	proteomic profiling by mass spectrometry	12	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 12	proteomic profiling by mass spectrometry	12	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 12	proteomic profiling by mass spectrometry	12	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 12	proteomic profiling by mass spectrometry	12	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 12	proteomic profiling by mass spectrometry	12	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 12	proteomic profiling by mass spectrometry	12	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 12	proteomic profiling by mass spectrometry	12	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 12	proteomic profiling by mass spectrometry	12	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 12	proteomic profiling by mass spectrometry	12	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 12	proteomic profiling by mass spectrometry	12	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 13	proteomic profiling by mass spectrometry	13	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 13	proteomic profiling by mass spectrometry	13	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 13	proteomic profiling by mass spectrometry	13	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 13	proteomic profiling by mass spectrometry	13	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 13	proteomic profiling by mass spectrometry	13	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 13	proteomic profiling by mass spectrometry	13	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 13	proteomic profiling by mass spectrometry	13	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 13	proteomic profiling by mass spectrometry	13	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 13	proteomic profiling by mass spectrometry	13	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 13	proteomic profiling by mass spectrometry	13	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 14	proteomic profiling by mass spectrometry	14	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 14	proteomic profiling by mass spectrometry	14	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 14	proteomic profiling by mass spectrometry	14	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 14	proteomic profiling by mass spectrometry	14	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 14	proteomic profiling by mass spectrometry	14	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 14	proteomic profiling by mass spectrometry	14	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 14	proteomic profiling by mass spectrometry	14	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 14	proteomic profiling by mass spectrometry	14	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 14	proteomic profiling by mass spectrometry	14	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 14	proteomic profiling by mass spectrometry	14	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 15	proteomic profiling by mass spectrometry	15	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 15	proteomic profiling by mass spectrometry	15	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 15	proteomic profiling by mass spectrometry	15	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 15	proteomic profiling by mass spectrometry	15	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 15	proteomic profiling by mass spectrometry	15	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 15	proteomic profiling by mass spectrometry	15	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 15	proteomic profiling by mass spectrometry	15	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 15	proteomic profiling by mass spectrometry	15	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 15	proteomic profiling by mass spectrometry	15	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 15	proteomic profiling by mass spectrometry	15	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 16	proteomic profiling by mass spectrometry	16	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 16	proteomic profiling by mass spectrometry	16	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 16	proteomic profiling by mass spectrometry	16	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 16	proteomic profiling by mass spectrometry	16	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 16	proteomic profiling by mass spectrometry	16	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 16	proteomic profiling by mass spectrometry	16	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 16	proteomic profiling by mass spectrometry	16	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 16	proteomic profiling by mass spectrometry	16	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 16	proteomic profiling by mass spectrometry	16	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 16	proteomic profiling by mass spectrometry	16	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 17	proteomic profiling by mass spectrometry	17	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 17	proteomic profiling by mass spectrometry	17	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 17	proteomic profiling by mass spectrometry	17	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 17	proteomic profiling by mass spectrometry	17	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 17	proteomic profiling by mass spectrometry	17	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 17	proteomic profiling by mass spectrometry	17	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 17	proteomic profiling by mass spectrometry	17	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 17	proteomic profiling by mass spectrometry	17	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 17	proteomic profiling by mass spectrometry	17	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 17	proteomic profiling by mass spectrometry	17	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 18	proteomic profiling by mass spectrometry	18	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 18	proteomic profiling by mass spectrometry	18	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 18	proteomic profiling by mass spectrometry	18	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 18	proteomic profiling by mass spectrometry	18	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 18	proteomic profiling by mass spectrometry	18	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 18	proteomic profiling by mass spectrometry	18	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 18	proteomic profiling by mass spectrometry	18	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 18	proteomic profiling by mass spectrometry	18	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 18	proteomic profiling by mass spectrometry	18	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 18	proteomic profiling by mass spectrometry	18	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 19	proteomic profiling by mass spectrometry	19	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 19	proteomic profiling by mass spectrometry	19	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 19	proteomic profiling by mass spectrometry	19	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 19	proteomic profiling by mass spectrometry	19	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 19	proteomic profiling by mass spectrometry	19	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 19	proteomic profiling by mass spectrometry	19	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 19	proteomic profiling by mass spectrometry	19	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 19	proteomic profiling by mass spectrometry	19	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 19	proteomic profiling by mass spectrometry	19	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 19	proteomic profiling by mass spectrometry	19	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 20	proteomic profiling by mass spectrometry	20	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 20	proteomic profiling by mass spectrometry	20	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 20	proteomic profiling by mass spectrometry	20	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 20	proteomic profiling by mass spectrometry	20	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 20	proteomic profiling by mass spectrometry	20	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 20	proteomic profiling by mass spectrometry	20	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 20	proteomic profiling by mass spectrometry	20	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 20	proteomic profiling by mass spectrometry	20	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 20	proteomic profiling by mass spectrometry	20	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 20	proteomic profiling by mass spectrometry	20	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 21	proteomic profiling by mass spectrometry	21	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 21	proteomic profiling by mass spectrometry	21	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 21	proteomic profiling by mass spectrometry	21	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 21	proteomic profiling by mass spectrometry	21	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 21	proteomic profiling by mass spectrometry	21	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 21	proteomic profiling by mass spectrometry	21	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 21	proteomic profiling by mass spectrometry	21	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 21	proteomic profiling by mass spectrometry	21	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 21	proteomic profiling by mass spectrometry	21	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 21	proteomic profiling by mass spectrometry	21	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 22	proteomic profiling by mass spectrometry	22	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 22	proteomic profiling by mass spectrometry	22	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 22	proteomic profiling by mass spectrometry	22	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 22	proteomic profiling by mass spectrometry	22	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 22	proteomic profiling by mass spectrometry	22	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 22	proteomic profiling by mass spectrometry	22	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 22	proteomic profiling by mass spectrometry	22	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 22	proteomic profiling by mass spectrometry	22	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 22	proteomic profiling by mass spectrometry	22	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 22	proteomic profiling by mass spectrometry	22	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 23	proteomic profiling by mass spectrometry	23	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 23	proteomic profiling by mass spectrometry	23	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 23	proteomic profiling by mass spectrometry	23	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 23	proteomic profiling by mass spectrometry	23	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 23	proteomic profiling by mass spectrometry	23	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 23	proteomic profiling by mass spectrometry	23	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 23	proteomic profiling by mass spectrometry	23	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 23	proteomic profiling by mass spectrometry	23	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 23	proteomic profiling by mass spectrometry	23	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 23	proteomic profiling by mass spectrometry	23	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 24	proteomic profiling by mass spectrometry	24	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 24	proteomic profiling by mass spectrometry	24	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 24	proteomic profiling by mass spectrometry	24	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 24	proteomic profiling by mass spectrometry	24	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 24	proteomic profiling by mass spectrometry	24	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 24	proteomic profiling by mass spectrometry	24	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 24	proteomic profiling by mass spectrometry	24	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 24	proteomic profiling by mass spectrometry	24	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 24	proteomic profiling by mass spectrometry	24	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 24	proteomic profiling by mass spectrometry	24	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 25	proteomic profiling by mass spectrometry	25	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 25	proteomic profiling by mass spectrometry	25	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 25	proteomic profiling by mass spectrometry	25	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 25	proteomic profiling by mass spectrometry	25	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 25	proteomic profiling by mass spectrometry	25	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 25	proteomic profiling by mass spectrometry	25	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 25	proteomic profiling by mass spectrometry	25	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 25	proteomic profiling by mass spectrometry	25	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 25	proteomic profiling by mass spectrometry	25	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 25	proteomic profiling by mass spectrometry	25	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 26	proteomic profiling by mass spectrometry	26	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 26	proteomic profiling by mass spectrometry	26	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 26	proteomic profiling by mass spectrometry	26	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 26	proteomic profiling by mass spectrometry	26	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 26	proteomic profiling by mass spectrometry	26	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 26	proteomic profiling by mass spectrometry	26	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 26	proteomic profiling by mass spectrometry	26	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 26	proteomic profiling by mass spectrometry	26	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 26	proteomic profiling by mass spectrometry	26	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 26	proteomic profiling by mass spectrometry	26	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 27	proteomic profiling by mass spectrometry	27	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 27	proteomic profiling by mass spectrometry	27	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 27	proteomic profiling by mass spectrometry	27	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 27	proteomic profiling by mass spectrometry	27	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 27	proteomic profiling by mass spectrometry	27	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 27	proteomic profiling by mass spectrometry	27	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 27	proteomic profiling by mass spectrometry	27	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 27	proteomic profiling by mass spectrometry	27	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 27	proteomic profiling by mass spectrometry	27	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 27	proteomic profiling by mass spectrometry	27	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 28	proteomic profiling by mass spectrometry	28	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 28	proteomic profiling by mass spectrometry	28	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 28	proteomic profiling by mass spectrometry	28	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 28	proteomic profiling by mass spectrometry	28	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 28	proteomic profiling by mass spectrometry	28	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 28	proteomic profiling by mass spectrometry	28	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 28	proteomic profiling by mass spectrometry	28	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 28	proteomic profiling by mass spectrometry	28	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 28	proteomic profiling by mass spectrometry	28	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 28	proteomic profiling by mass spectrometry	28	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 29	proteomic profiling by mass spectrometry	29	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 29	proteomic profiling by mass spectrometry	29	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 29	proteomic profiling by mass spectrometry	29	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 29	proteomic profiling by mass spectrometry	29	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 29	proteomic profiling by mass spectrometry	29	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 29	proteomic profiling by mass spectrometry	29	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 29	proteomic profiling by mass spectrometry	29	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 29	proteomic profiling by mass spectrometry	29	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 29	proteomic profiling by mass spectrometry	29	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 29	proteomic profiling by mass spectrometry	29	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 30	proteomic profiling by mass spectrometry	30	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 30	proteomic profiling by mass spectrometry	30	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 30	proteomic profiling by mass spectrometry	30	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 30	proteomic profiling by mass spectrometry	30	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 30	proteomic profiling by mass spectrometry	30	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 30	proteomic profiling by mass spectrometry	30	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 30	proteomic profiling by mass spectrometry	30	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 30	proteomic profiling by mass spectrometry	30	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 30	proteomic profiling by mass spectrometry	30	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 30	proteomic profiling by mass spectrometry	30	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 31	proteomic profiling by mass spectrometry	31	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 31	proteomic profiling by mass spectrometry	31	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 31	proteomic profiling by mass spectrometry	31	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 31	proteomic profiling by mass spectrometry	31	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 31	proteomic profiling by mass spectrometry	31	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 31	proteomic profiling by mass spectrometry	31	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 31	proteomic profiling by mass spectrometry	31	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 31	proteomic profiling by mass spectrometry	31	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 31	proteomic profiling by mass spectrometry	31	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 31	proteomic profiling by mass spectrometry	31	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 32	proteomic profiling by mass spectrometry	32	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 32	proteomic profiling by mass spectrometry	32	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 32	proteomic profiling by mass spectrometry	32	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 32	proteomic profiling by mass spectrometry	32	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 32	proteomic profiling by mass spectrometry	32	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 32	proteomic profiling by mass spectrometry	32	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 32	proteomic profiling by mass spectrometry	32	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 32	proteomic profiling by mass spectrometry	32	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 32	proteomic profiling by mass spectrometry	32	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 32	proteomic profiling by mass spectrometry	32	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 33	proteomic profiling by mass spectrometry	33	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 33	proteomic profiling by mass spectrometry	33	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 33	proteomic profiling by mass spectrometry	33	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 33	proteomic profiling by mass spectrometry	33	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 33	proteomic profiling by mass spectrometry	33	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 33	proteomic profiling by mass spectrometry	33	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 33	proteomic profiling by mass spectrometry	33	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 33	proteomic profiling by mass spectrometry	33	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 33	proteomic profiling by mass spectrometry	33	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 33	proteomic profiling by mass spectrometry	33	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 34	proteomic profiling by mass spectrometry	34	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 34	proteomic profiling by mass spectrometry	34	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 34	proteomic profiling by mass spectrometry	34	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 34	proteomic profiling by mass spectrometry	34	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 34	proteomic profiling by mass spectrometry	34	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 34	proteomic profiling by mass spectrometry	34	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 34	proteomic profiling by mass spectrometry	34	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 34	proteomic profiling by mass spectrometry	34	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 34	proteomic profiling by mass spectrometry	34	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 34	proteomic profiling by mass spectrometry	34	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 35	proteomic profiling by mass spectrometry	35	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 35	proteomic profiling by mass spectrometry	35	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 35	proteomic profiling by mass spectrometry	35	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 35	proteomic profiling by mass spectrometry	35	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 35	proteomic profiling by mass spectrometry	35	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 35	proteomic profiling by mass spectrometry	35	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 35	proteomic profiling by mass spectrometry	35	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 35	proteomic profiling by mass spectrometry	35	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 35	proteomic profiling by mass spectrometry	35	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 35	proteomic profiling by mass spectrometry	35	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 36	proteomic profiling by mass spectrometry	36	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 36	proteomic profiling by mass spectrometry	36	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 36	proteomic profiling by mass spectrometry	36	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 36	proteomic profiling by mass spectrometry	36	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 36	proteomic profiling by mass spectrometry	36	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 36	proteomic profiling by mass spectrometry	36	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 36	proteomic profiling by mass spectrometry	36	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 36	proteomic profiling by mass spectrometry	36	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 36	proteomic profiling by mass spectrometry	36	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 36	proteomic profiling by mass spectrometry	36	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 37	proteomic profiling by mass spectrometry	37	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 37	proteomic profiling by mass spectrometry	37	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 37	proteomic profiling by mass spectrometry	37	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 37	proteomic profiling by mass spectrometry	37	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 37	proteomic profiling by mass spectrometry	37	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 37	proteomic profiling by mass spectrometry	37	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 37	proteomic profiling by mass spectrometry	37	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 37	proteomic profiling by mass spectrometry	37	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 37	proteomic profiling by mass spectrometry	37	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 37	proteomic profiling by mass spectrometry	37	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 38	proteomic profiling by mass spectrometry	38	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 38	proteomic profiling by mass spectrometry	38	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 38	proteomic profiling by mass spectrometry	38	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 38	proteomic profiling by mass spectrometry	38	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 38	proteomic profiling by mass spectrometry	38	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 38	proteomic profiling by mass spectrometry	38	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 38	proteomic profiling by mass spectrometry	38	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 38	proteomic profiling by mass spectrometry	38	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 38	proteomic profiling by mass spectrometry	38	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 38	proteomic profiling by mass spectrometry	38	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 39	proteomic profiling by mass spectrometry	39	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 39	proteomic profiling by mass spectrometry	39	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 39	proteomic profiling by mass spectrometry	39	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 39	proteomic profiling by mass spectrometry	39	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 39	proteomic profiling by mass spectrometry	39	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 39	proteomic profiling by mass spectrometry	39	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 39	proteomic profiling by mass spectrometry	39	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 39	proteomic profiling by mass spectrometry	39	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 39	proteomic profiling by mass spectrometry	39	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 39	proteomic profiling by mass spectrometry	39	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 40	proteomic profiling by mass spectrometry	40	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 40	proteomic profiling by mass spectrometry	40	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 40	proteomic profiling by mass spectrometry	40	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 40	proteomic profiling by mass spectrometry	40	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 40	proteomic profiling by mass spectrometry	40	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 40	proteomic profiling by mass spectrometry	40	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 40	proteomic profiling by mass spectrometry	40	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 40	proteomic profiling by mass spectrometry	40	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 40	proteomic profiling by mass spectrometry	40	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 40	proteomic profiling by mass spectrometry	40	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 41	proteomic profiling by mass spectrometry	41	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 41	proteomic profiling by mass spectrometry	41	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 41	proteomic profiling by mass spectrometry	41	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 41	proteomic profiling by mass spectrometry	41	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 41	proteomic profiling by mass spectrometry	41	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 41	proteomic profiling by mass spectrometry	41	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 41	proteomic profiling by mass spectrometry	41	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 41	proteomic profiling by mass spectrometry	41	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 41	proteomic profiling by mass spectrometry	41	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 41	proteomic profiling by mass spectrometry	41	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 42	proteomic profiling by mass spectrometry	42	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 42	proteomic profiling by mass spectrometry	42	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 42	proteomic profiling by mass spectrometry	42	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 42	proteomic profiling by mass spectrometry	42	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 42	proteomic profiling by mass spectrometry	42	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 42	proteomic profiling by mass spectrometry	42	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 42	proteomic profiling by mass spectrometry	42	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 42	proteomic profiling by mass spectrometry	42	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 42	proteomic profiling by mass spectrometry	42	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 42	proteomic profiling by mass spectrometry	42	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 43	proteomic profiling by mass spectrometry	43	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 43	proteomic profiling by mass spectrometry	43	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 43	proteomic profiling by mass spectrometry	43	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 43	proteomic profiling by mass spectrometry	43	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 43	proteomic profiling by mass spectrometry	43	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 43	proteomic profiling by mass spectrometry	43	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 43	proteomic profiling by mass spectrometry	43	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 43	proteomic profiling by mass spectrometry	43	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 43	proteomic profiling by mass spectrometry	43	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 43	proteomic profiling by mass spectrometry	43	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 44	proteomic profiling by mass spectrometry	44	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 44	proteomic profiling by mass spectrometry	44	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 44	proteomic profiling by mass spectrometry	44	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 44	proteomic profiling by mass spectrometry	44	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 44	proteomic profiling by mass spectrometry	44	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 44	proteomic profiling by mass spectrometry	44	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 44	proteomic profiling by mass spectrometry	44	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 44	proteomic profiling by mass spectrometry	44	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 44	proteomic profiling by mass spectrometry	44	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 44	proteomic profiling by mass spectrometry	44	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 45	proteomic profiling by mass spectrometry	45	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 45	proteomic profiling by mass spectrometry	45	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 45	proteomic profiling by mass spectrometry	45	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 45	proteomic profiling by mass spectrometry	45	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 45	proteomic profiling by mass spectrometry	45	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 45	proteomic profiling by mass spectrometry	45	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 45	proteomic profiling by mass spectrometry	45	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 45	proteomic profiling by mass spectrometry	45	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 45	proteomic profiling by mass spectrometry	45	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 45	proteomic profiling by mass spectrometry	45	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 46	proteomic profiling by mass spectrometry	46	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 46	proteomic profiling by mass spectrometry	46	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 46	proteomic profiling by mass spectrometry	46	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 46	proteomic profiling by mass spectrometry	46	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 46	proteomic profiling by mass spectrometry	46	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 46	proteomic profiling by mass spectrometry	46	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 46	proteomic profiling by mass spectrometry	46	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 46	proteomic profiling by mass spectrometry	46	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 46	proteomic profiling by mass spectrometry	46	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 46	proteomic profiling by mass spectrometry	46	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 47	proteomic profiling by mass spectrometry	47	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 47	proteomic profiling by mass spectrometry	47	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 47	proteomic profiling by mass spectrometry	47	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 47	proteomic profiling by mass spectrometry	47	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 47	proteomic profiling by mass spectrometry	47	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 47	proteomic profiling by mass spectrometry	47	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 47	proteomic profiling by mass spectrometry	47	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 47	proteomic profiling by mass spectrometry	47	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 47	proteomic profiling by mass spectrometry	47	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 47	proteomic profiling by mass spectrometry	47	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 48	proteomic profiling by mass spectrometry	48	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 48	proteomic profiling by mass spectrometry	48	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 48	proteomic profiling by mass spectrometry	48	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 48	proteomic profiling by mass spectrometry	48	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 48	proteomic profiling by mass spectrometry	48	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 48	proteomic profiling by mass spectrometry	48	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 48	proteomic profiling by mass spectrometry	48	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 48	proteomic profiling by mass spectrometry	48	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 48	proteomic profiling by mass spectrometry	48	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 48	proteomic profiling by mass spectrometry	48	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 49	proteomic profiling by mass spectrometry	49	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 49	proteomic profiling by mass spectrometry	49	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 49	proteomic profiling by mass spectrometry	49	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 49	proteomic profiling by mass spectrometry	49	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 49	proteomic profiling by mass spectrometry	49	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 49	proteomic profiling by mass spectrometry	49	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 49	proteomic profiling by mass spectrometry	49	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 49	proteomic profiling by mass spectrometry	49	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 49	proteomic profiling by mass spectrometry	49	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 49	proteomic profiling by mass spectrometry	49	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 50	proteomic profiling by mass spectrometry	50	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 50	proteomic profiling by mass spectrometry	50	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 50	proteomic profiling by mass spectrometry	50	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 50	proteomic profiling by mass spectrometry	50	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 50	proteomic profiling by mass spectrometry	50	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 50	proteomic profiling by mass spectrometry	50	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 50	proteomic profiling by mass spectrometry	50	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 50	proteomic profiling by mass spectrometry	50	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 50	proteomic profiling by mass spectrometry	50	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 50	proteomic profiling by mass spectrometry	50	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 51	proteomic profiling by mass spectrometry	51	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 51	proteomic profiling by mass spectrometry	51	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 51	proteomic profiling by mass spectrometry	51	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 51	proteomic profiling by mass spectrometry	51	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 51	proteomic profiling by mass spectrometry	51	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 51	proteomic profiling by mass spectrometry	51	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 51	proteomic profiling by mass spectrometry	51	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 51	proteomic profiling by mass spectrometry	51	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 51	proteomic profiling by mass spectrometry	51	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 51	proteomic profiling by mass spectrometry	51	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 52	proteomic profiling by mass spectrometry	52	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 52	proteomic profiling by mass spectrometry	52	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 52	proteomic profiling by mass spectrometry	52	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 52	proteomic profiling by mass spectrometry	52	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 52	proteomic profiling by mass spectrometry	52	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 52	proteomic profiling by mass spectrometry	52	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 52	proteomic profiling by mass spectrometry	52	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 52	proteomic profiling by mass spectrometry	52	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 52	proteomic profiling by mass spectrometry	52	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 52	proteomic profiling by mass spectrometry	52	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 53	proteomic profiling by mass spectrometry	53	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 53	proteomic profiling by mass spectrometry	53	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 53	proteomic profiling by mass spectrometry	53	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 53	proteomic profiling by mass spectrometry	53	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 53	proteomic profiling by mass spectrometry	53	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 53	proteomic profiling by mass spectrometry	53	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 53	proteomic profiling by mass spectrometry	53	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 53	proteomic profiling by mass spectrometry	53	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 53	proteomic profiling by mass spectrometry	53	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 53	proteomic profiling by mass spectrometry	53	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 54	proteomic profiling by mass spectrometry	54	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 54	proteomic profiling by mass spectrometry	54	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 54	proteomic profiling by mass spectrometry	54	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 54	proteomic profiling by mass spectrometry	54	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 54	proteomic profiling by mass spectrometry	54	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 54	proteomic profiling by mass spectrometry	54	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 54	proteomic profiling by mass spectrometry	54	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 54	proteomic profiling by mass spectrometry	54	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 54	proteomic profiling by mass spectrometry	54	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 54	proteomic profiling by mass spectrometry	54	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 55	proteomic profiling by mass spectrometry	55	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 55	proteomic profiling by mass spectrometry	55	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 55	proteomic profiling by mass spectrometry	55	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 55	proteomic profiling by mass spectrometry	55	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 55	proteomic profiling by mass spectrometry	55	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 55	proteomic profiling by mass spectrometry	55	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 55	proteomic profiling by mass spectrometry	55	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 55	proteomic profiling by mass spectrometry	55	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 55	proteomic profiling by mass spectrometry	55	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 55	proteomic profiling by mass spectrometry	55	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 56	proteomic profiling by mass spectrometry	56	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 56	proteomic profiling by mass spectrometry	56	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 56	proteomic profiling by mass spectrometry	56	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 56	proteomic profiling by mass spectrometry	56	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 56	proteomic profiling by mass spectrometry	56	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 56	proteomic profiling by mass spectrometry	56	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 56	proteomic profiling by mass spectrometry	56	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 56	proteomic profiling by mass spectrometry	56	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 56	proteomic profiling by mass spectrometry	56	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 56	proteomic profiling by mass spectrometry	56	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 57	proteomic profiling by mass spectrometry	57	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 57	proteomic profiling by mass spectrometry	57	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 57	proteomic profiling by mass spectrometry	57	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 57	proteomic profiling by mass spectrometry	57	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 57	proteomic profiling by mass spectrometry	57	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 57	proteomic profiling by mass spectrometry	57	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 57	proteomic profiling by mass spectrometry	57	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 57	proteomic profiling by mass spectrometry	57	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 57	proteomic profiling by mass spectrometry	57	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 57	proteomic profiling by mass spectrometry	57	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 58	proteomic profiling by mass spectrometry	58	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 58	proteomic profiling by mass spectrometry	58	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 58	proteomic profiling by mass spectrometry	58	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 58	proteomic profiling by mass spectrometry	58	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 58	proteomic profiling by mass spectrometry	58	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 58	proteomic profiling by mass spectrometry	58	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 58	proteomic profiling by mass spectrometry	58	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 58	proteomic profiling by mass spectrometry	58	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 58	proteomic profiling by mass spectrometry	58	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 58	proteomic profiling by mass spectrometry	58	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 59	proteomic profiling by mass spectrometry	59	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 59	proteomic profiling by mass spectrometry	59	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 59	proteomic profiling by mass spectrometry	59	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 59	proteomic profiling by mass spectrometry	59	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 59	proteomic profiling by mass spectrometry	59	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 59	proteomic profiling by mass spectrometry	59	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 59	proteomic profiling by mass spectrometry	59	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 59	proteomic profiling by mass spectrometry	59	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 59	proteomic profiling by mass spectrometry	59	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 59	proteomic profiling by mass spectrometry	59	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 60	proteomic profiling by mass spectrometry	60	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 60	proteomic profiling by mass spectrometry	60	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 60	proteomic profiling by mass spectrometry	60	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 60	proteomic profiling by mass spectrometry	60	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 60	proteomic profiling by mass spectrometry	60	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 60	proteomic profiling by mass spectrometry	60	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 60	proteomic profiling by mass spectrometry	60	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 60	proteomic profiling by mass spectrometry	60	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 60	proteomic profiling by mass spectrometry	60	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 60	proteomic profiling by mass spectrometry	60	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 61	proteomic profiling by mass spectrometry	61	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 61	proteomic profiling by mass spectrometry	61	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 61	proteomic profiling by mass spectrometry	61	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 61	proteomic profiling by mass spectrometry	61	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 61	proteomic profiling by mass spectrometry	61	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 61	proteomic profiling by mass spectrometry	61	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 61	proteomic profiling by mass spectrometry	61	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 61	proteomic profiling by mass spectrometry	61	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 61	proteomic profiling by mass spectrometry	61	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 61	proteomic profiling by mass spectrometry	61	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 62	proteomic profiling by mass spectrometry	62	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 62	proteomic profiling by mass spectrometry	62	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 62	proteomic profiling by mass spectrometry	62	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 62	proteomic profiling by mass spectrometry	62	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 62	proteomic profiling by mass spectrometry	62	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 62	proteomic profiling by mass spectrometry	62	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 62	proteomic profiling by mass spectrometry	62	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 62	proteomic profiling by mass spectrometry	62	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 62	proteomic profiling by mass spectrometry	62	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 62	proteomic profiling by mass spectrometry	62	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 63	proteomic profiling by mass spectrometry	63	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 63	proteomic profiling by mass spectrometry	63	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 63	proteomic profiling by mass spectrometry	63	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 63	proteomic profiling by mass spectrometry	63	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 63	proteomic profiling by mass spectrometry	63	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 63	proteomic profiling by mass spectrometry	63	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 63	proteomic profiling by mass spectrometry	63	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 63	proteomic profiling by mass spectrometry	63	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 63	proteomic profiling by mass spectrometry	63	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 63	proteomic profiling by mass spectrometry	63	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 64	proteomic profiling by mass spectrometry	64	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 64	proteomic profiling by mass spectrometry	64	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 64	proteomic profiling by mass spectrometry	64	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 64	proteomic profiling by mass spectrometry	64	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 64	proteomic profiling by mass spectrometry	64	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 64	proteomic profiling by mass spectrometry	64	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 64	proteomic profiling by mass spectrometry	64	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 64	proteomic profiling by mass spectrometry	64	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 64	proteomic profiling by mass spectrometry	64	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 64	proteomic profiling by mass spectrometry	64	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 65	proteomic profiling by mass spectrometry	65	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 65	proteomic profiling by mass spectrometry	65	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 65	proteomic profiling by mass spectrometry	65	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 65	proteomic profiling by mass spectrometry	65	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 65	proteomic profiling by mass spectrometry	65	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 65	proteomic profiling by mass spectrometry	65	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 65	proteomic profiling by mass spectrometry	65	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 65	proteomic profiling by mass spectrometry	65	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 65	proteomic profiling by mass spectrometry	65	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 65	proteomic profiling by mass spectrometry	65	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 66	proteomic profiling by mass spectrometry	66	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 66	proteomic profiling by mass spectrometry	66	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 66	proteomic profiling by mass spectrometry	66	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 66	proteomic profiling by mass spectrometry	66	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 66	proteomic profiling by mass spectrometry	66	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 66	proteomic profiling by mass spectrometry	66	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 66	proteomic profiling by mass spectrometry	66	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 66	proteomic profiling by mass spectrometry	66	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 66	proteomic profiling by mass spectrometry	66	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 66	proteomic profiling by mass spectrometry	66	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 67	proteomic profiling by mass spectrometry	67	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 67	proteomic profiling by mass spectrometry	67	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 67	proteomic profiling by mass spectrometry	67	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 67	proteomic profiling by mass spectrometry	67	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 67	proteomic profiling by mass spectrometry	67	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 67	proteomic profiling by mass spectrometry	67	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 67	proteomic profiling by mass spectrometry	67	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 67	proteomic profiling by mass spectrometry	67	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 67	proteomic profiling by mass spectrometry	67	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 67	proteomic profiling by mass spectrometry	67	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 68	proteomic profiling by mass spectrometry	68	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 68	proteomic profiling by mass spectrometry	68	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 68	proteomic profiling by mass spectrometry	68	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 68	proteomic profiling by mass spectrometry	68	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 68	proteomic profiling by mass spectrometry	68	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 68	proteomic profiling by mass spectrometry	68	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 68	proteomic profiling by mass spectrometry	68	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 68	proteomic profiling by mass spectrometry	68	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 68	proteomic profiling by mass spectrometry	68	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 68	proteomic profiling by mass spectrometry	68	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 69	proteomic profiling by mass spectrometry	69	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 69	proteomic profiling by mass spectrometry	69	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 69	proteomic profiling by mass spectrometry	69	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 69	proteomic profiling by mass spectrometry	69	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 69	proteomic profiling by mass spectrometry	69	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 69	proteomic profiling by mass spectrometry	69	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 69	proteomic profiling by mass spectrometry	69	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 69	proteomic profiling by mass spectrometry	69	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 69	proteomic profiling by mass spectrometry	69	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 69	proteomic profiling by mass spectrometry	69	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 70	proteomic profiling by mass spectrometry	70	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 70	proteomic profiling by mass spectrometry	70	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 70	proteomic profiling by mass spectrometry	70	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 70	proteomic profiling by mass spectrometry	70	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 70	proteomic profiling by mass spectrometry	70	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 70	proteomic profiling by mass spectrometry	70	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 70	proteomic profiling by mass spectrometry	70	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 70	proteomic profiling by mass spectrometry	70	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 70	proteomic profiling by mass spectrometry	70	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 70	proteomic profiling by mass spectrometry	70	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 71	proteomic profiling by mass spectrometry	71	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 71	proteomic profiling by mass spectrometry	71	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 71	proteomic profiling by mass spectrometry	71	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 71	proteomic profiling by mass spectrometry	71	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 71	proteomic profiling by mass spectrometry	71	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 71	proteomic profiling by mass spectrometry	71	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 71	proteomic profiling by mass spectrometry	71	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 71	proteomic profiling by mass spectrometry	71	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 71	proteomic profiling by mass spectrometry	71	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 71	proteomic profiling by mass spectrometry	71	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 1	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_012	tissue	run 72	proteomic profiling by mass spectrometry	72	TMT126	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 2	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_012	tissue	run 72	proteomic profiling by mass spectrometry	72	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 3	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_038	tissue	run 72	proteomic profiling by mass spectrometry	72	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 4	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_038	tissue	run 72	proteomic profiling by mass spectrometry	72	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 5	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_065	tissue	run 72	proteomic profiling by mass spectrometry	72	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 6	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_065	tissue	run 72	proteomic profiling by mass spectrometry	72	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 7	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_069	tissue	run 72	proteomic profiling by mass spectrometry	72	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 8	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_069	tissue	run 72	proteomic profiling by mass spectrometry	72	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 9	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_057	tissue	run 72	proteomic profiling by mass spectrometry	72	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 10	Homo sapiens	blood plasma	1	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS1	tissue	run 72	proteomic profiling by mass spectrometry	72	TMT131	LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set1_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 73	proteomic profiling by mass spectrometry	1	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 73	proteomic profiling by mass spectrometry	1	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 73	proteomic profiling by mass spectrometry	1	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 73	proteomic profiling by mass spectrometry	1	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 73	proteomic profiling by mass spectrometry	1	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 73	proteomic profiling by mass spectrometry	1	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 73	proteomic profiling by mass spectrometry	1	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 73	proteomic profiling by mass spectrometry	1	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 73	proteomic profiling by mass spectrometry	1	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 73	proteomic profiling by mass spectrometry	1	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 74	proteomic profiling by mass spectrometry	2	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 74	proteomic profiling by mass spectrometry	2	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 74	proteomic profiling by mass spectrometry	2	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 74	proteomic profiling by mass spectrometry	2	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 74	proteomic profiling by mass spectrometry	2	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 74	proteomic profiling by mass spectrometry	2	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 74	proteomic profiling by mass spectrometry	2	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 74	proteomic profiling by mass spectrometry	2	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 74	proteomic profiling by mass spectrometry	2	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 74	proteomic profiling by mass spectrometry	2	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 75	proteomic profiling by mass spectrometry	3	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 75	proteomic profiling by mass spectrometry	3	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 75	proteomic profiling by mass spectrometry	3	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 75	proteomic profiling by mass spectrometry	3	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 75	proteomic profiling by mass spectrometry	3	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 75	proteomic profiling by mass spectrometry	3	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 75	proteomic profiling by mass spectrometry	3	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 75	proteomic profiling by mass spectrometry	3	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 75	proteomic profiling by mass spectrometry	3	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 75	proteomic profiling by mass spectrometry	3	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 76	proteomic profiling by mass spectrometry	4	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 76	proteomic profiling by mass spectrometry	4	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 76	proteomic profiling by mass spectrometry	4	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 76	proteomic profiling by mass spectrometry	4	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 76	proteomic profiling by mass spectrometry	4	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 76	proteomic profiling by mass spectrometry	4	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 76	proteomic profiling by mass spectrometry	4	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 76	proteomic profiling by mass spectrometry	4	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 76	proteomic profiling by mass spectrometry	4	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 76	proteomic profiling by mass spectrometry	4	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 77	proteomic profiling by mass spectrometry	5	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 77	proteomic profiling by mass spectrometry	5	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 77	proteomic profiling by mass spectrometry	5	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 77	proteomic profiling by mass spectrometry	5	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 77	proteomic profiling by mass spectrometry	5	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 77	proteomic profiling by mass spectrometry	5	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 77	proteomic profiling by mass spectrometry	5	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 77	proteomic profiling by mass spectrometry	5	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 77	proteomic profiling by mass spectrometry	5	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 77	proteomic profiling by mass spectrometry	5	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 78	proteomic profiling by mass spectrometry	6	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 78	proteomic profiling by mass spectrometry	6	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 78	proteomic profiling by mass spectrometry	6	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 78	proteomic profiling by mass spectrometry	6	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 78	proteomic profiling by mass spectrometry	6	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 78	proteomic profiling by mass spectrometry	6	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 78	proteomic profiling by mass spectrometry	6	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 78	proteomic profiling by mass spectrometry	6	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 78	proteomic profiling by mass spectrometry	6	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 78	proteomic profiling by mass spectrometry	6	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 79	proteomic profiling by mass spectrometry	7	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 79	proteomic profiling by mass spectrometry	7	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 79	proteomic profiling by mass spectrometry	7	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 79	proteomic profiling by mass spectrometry	7	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 79	proteomic profiling by mass spectrometry	7	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 79	proteomic profiling by mass spectrometry	7	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 79	proteomic profiling by mass spectrometry	7	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 79	proteomic profiling by mass spectrometry	7	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 79	proteomic profiling by mass spectrometry	7	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 79	proteomic profiling by mass spectrometry	7	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 80	proteomic profiling by mass spectrometry	8	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 80	proteomic profiling by mass spectrometry	8	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 80	proteomic profiling by mass spectrometry	8	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 80	proteomic profiling by mass spectrometry	8	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 80	proteomic profiling by mass spectrometry	8	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 80	proteomic profiling by mass spectrometry	8	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 80	proteomic profiling by mass spectrometry	8	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 80	proteomic profiling by mass spectrometry	8	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 80	proteomic profiling by mass spectrometry	8	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 80	proteomic profiling by mass spectrometry	8	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 81	proteomic profiling by mass spectrometry	9	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 81	proteomic profiling by mass spectrometry	9	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 81	proteomic profiling by mass spectrometry	9	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 81	proteomic profiling by mass spectrometry	9	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 81	proteomic profiling by mass spectrometry	9	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 81	proteomic profiling by mass spectrometry	9	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 81	proteomic profiling by mass spectrometry	9	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 81	proteomic profiling by mass spectrometry	9	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 81	proteomic profiling by mass spectrometry	9	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 81	proteomic profiling by mass spectrometry	9	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 82	proteomic profiling by mass spectrometry	10	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 82	proteomic profiling by mass spectrometry	10	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 82	proteomic profiling by mass spectrometry	10	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 82	proteomic profiling by mass spectrometry	10	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 82	proteomic profiling by mass spectrometry	10	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 82	proteomic profiling by mass spectrometry	10	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 82	proteomic profiling by mass spectrometry	10	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 82	proteomic profiling by mass spectrometry	10	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 82	proteomic profiling by mass spectrometry	10	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 82	proteomic profiling by mass spectrometry	10	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 83	proteomic profiling by mass spectrometry	11	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 83	proteomic profiling by mass spectrometry	11	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 83	proteomic profiling by mass spectrometry	11	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 83	proteomic profiling by mass spectrometry	11	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 83	proteomic profiling by mass spectrometry	11	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 83	proteomic profiling by mass spectrometry	11	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 83	proteomic profiling by mass spectrometry	11	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 83	proteomic profiling by mass spectrometry	11	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 83	proteomic profiling by mass spectrometry	11	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 83	proteomic profiling by mass spectrometry	11	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 84	proteomic profiling by mass spectrometry	12	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 84	proteomic profiling by mass spectrometry	12	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 84	proteomic profiling by mass spectrometry	12	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 84	proteomic profiling by mass spectrometry	12	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 84	proteomic profiling by mass spectrometry	12	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 84	proteomic profiling by mass spectrometry	12	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 84	proteomic profiling by mass spectrometry	12	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 84	proteomic profiling by mass spectrometry	12	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 84	proteomic profiling by mass spectrometry	12	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 84	proteomic profiling by mass spectrometry	12	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 85	proteomic profiling by mass spectrometry	13	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 85	proteomic profiling by mass spectrometry	13	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 85	proteomic profiling by mass spectrometry	13	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 85	proteomic profiling by mass spectrometry	13	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 85	proteomic profiling by mass spectrometry	13	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 85	proteomic profiling by mass spectrometry	13	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 85	proteomic profiling by mass spectrometry	13	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 85	proteomic profiling by mass spectrometry	13	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 85	proteomic profiling by mass spectrometry	13	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 85	proteomic profiling by mass spectrometry	13	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 86	proteomic profiling by mass spectrometry	14	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 86	proteomic profiling by mass spectrometry	14	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 86	proteomic profiling by mass spectrometry	14	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 86	proteomic profiling by mass spectrometry	14	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 86	proteomic profiling by mass spectrometry	14	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 86	proteomic profiling by mass spectrometry	14	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 86	proteomic profiling by mass spectrometry	14	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 86	proteomic profiling by mass spectrometry	14	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 86	proteomic profiling by mass spectrometry	14	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 86	proteomic profiling by mass spectrometry	14	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 87	proteomic profiling by mass spectrometry	15	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 87	proteomic profiling by mass spectrometry	15	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 87	proteomic profiling by mass spectrometry	15	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 87	proteomic profiling by mass spectrometry	15	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 87	proteomic profiling by mass spectrometry	15	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 87	proteomic profiling by mass spectrometry	15	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 87	proteomic profiling by mass spectrometry	15	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 87	proteomic profiling by mass spectrometry	15	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 87	proteomic profiling by mass spectrometry	15	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 87	proteomic profiling by mass spectrometry	15	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 88	proteomic profiling by mass spectrometry	16	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 88	proteomic profiling by mass spectrometry	16	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 88	proteomic profiling by mass spectrometry	16	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 88	proteomic profiling by mass spectrometry	16	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 88	proteomic profiling by mass spectrometry	16	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 88	proteomic profiling by mass spectrometry	16	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 88	proteomic profiling by mass spectrometry	16	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 88	proteomic profiling by mass spectrometry	16	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 88	proteomic profiling by mass spectrometry	16	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 88	proteomic profiling by mass spectrometry	16	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 89	proteomic profiling by mass spectrometry	17	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 89	proteomic profiling by mass spectrometry	17	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 89	proteomic profiling by mass spectrometry	17	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 89	proteomic profiling by mass spectrometry	17	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 89	proteomic profiling by mass spectrometry	17	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 89	proteomic profiling by mass spectrometry	17	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 89	proteomic profiling by mass spectrometry	17	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 89	proteomic profiling by mass spectrometry	17	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 89	proteomic profiling by mass spectrometry	17	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 89	proteomic profiling by mass spectrometry	17	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 90	proteomic profiling by mass spectrometry	18	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 90	proteomic profiling by mass spectrometry	18	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 90	proteomic profiling by mass spectrometry	18	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 90	proteomic profiling by mass spectrometry	18	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 90	proteomic profiling by mass spectrometry	18	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 90	proteomic profiling by mass spectrometry	18	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 90	proteomic profiling by mass spectrometry	18	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 90	proteomic profiling by mass spectrometry	18	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 90	proteomic profiling by mass spectrometry	18	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 90	proteomic profiling by mass spectrometry	18	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 91	proteomic profiling by mass spectrometry	19	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 91	proteomic profiling by mass spectrometry	19	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 91	proteomic profiling by mass spectrometry	19	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 91	proteomic profiling by mass spectrometry	19	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 91	proteomic profiling by mass spectrometry	19	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 91	proteomic profiling by mass spectrometry	19	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 91	proteomic profiling by mass spectrometry	19	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 91	proteomic profiling by mass spectrometry	19	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 91	proteomic profiling by mass spectrometry	19	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 91	proteomic profiling by mass spectrometry	19	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 92	proteomic profiling by mass spectrometry	20	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 92	proteomic profiling by mass spectrometry	20	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 92	proteomic profiling by mass spectrometry	20	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 92	proteomic profiling by mass spectrometry	20	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 92	proteomic profiling by mass spectrometry	20	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 92	proteomic profiling by mass spectrometry	20	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 92	proteomic profiling by mass spectrometry	20	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 92	proteomic profiling by mass spectrometry	20	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 92	proteomic profiling by mass spectrometry	20	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 92	proteomic profiling by mass spectrometry	20	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 93	proteomic profiling by mass spectrometry	21	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 93	proteomic profiling by mass spectrometry	21	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 93	proteomic profiling by mass spectrometry	21	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 93	proteomic profiling by mass spectrometry	21	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 93	proteomic profiling by mass spectrometry	21	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 93	proteomic profiling by mass spectrometry	21	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 93	proteomic profiling by mass spectrometry	21	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 93	proteomic profiling by mass spectrometry	21	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 93	proteomic profiling by mass spectrometry	21	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 93	proteomic profiling by mass spectrometry	21	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 94	proteomic profiling by mass spectrometry	22	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 94	proteomic profiling by mass spectrometry	22	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 94	proteomic profiling by mass spectrometry	22	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 94	proteomic profiling by mass spectrometry	22	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 94	proteomic profiling by mass spectrometry	22	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 94	proteomic profiling by mass spectrometry	22	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 94	proteomic profiling by mass spectrometry	22	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 94	proteomic profiling by mass spectrometry	22	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 94	proteomic profiling by mass spectrometry	22	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 94	proteomic profiling by mass spectrometry	22	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 95	proteomic profiling by mass spectrometry	23	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 95	proteomic profiling by mass spectrometry	23	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 95	proteomic profiling by mass spectrometry	23	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 95	proteomic profiling by mass spectrometry	23	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 95	proteomic profiling by mass spectrometry	23	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 95	proteomic profiling by mass spectrometry	23	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 95	proteomic profiling by mass spectrometry	23	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 95	proteomic profiling by mass spectrometry	23	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 95	proteomic profiling by mass spectrometry	23	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 95	proteomic profiling by mass spectrometry	23	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 96	proteomic profiling by mass spectrometry	24	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 96	proteomic profiling by mass spectrometry	24	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 96	proteomic profiling by mass spectrometry	24	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 96	proteomic profiling by mass spectrometry	24	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 96	proteomic profiling by mass spectrometry	24	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 96	proteomic profiling by mass spectrometry	24	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 96	proteomic profiling by mass spectrometry	24	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 96	proteomic profiling by mass spectrometry	24	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 96	proteomic profiling by mass spectrometry	24	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 96	proteomic profiling by mass spectrometry	24	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 97	proteomic profiling by mass spectrometry	25	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 97	proteomic profiling by mass spectrometry	25	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 97	proteomic profiling by mass spectrometry	25	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 97	proteomic profiling by mass spectrometry	25	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 97	proteomic profiling by mass spectrometry	25	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 97	proteomic profiling by mass spectrometry	25	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 97	proteomic profiling by mass spectrometry	25	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 97	proteomic profiling by mass spectrometry	25	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 97	proteomic profiling by mass spectrometry	25	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 97	proteomic profiling by mass spectrometry	25	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 98	proteomic profiling by mass spectrometry	26	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 98	proteomic profiling by mass spectrometry	26	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 98	proteomic profiling by mass spectrometry	26	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 98	proteomic profiling by mass spectrometry	26	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 98	proteomic profiling by mass spectrometry	26	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 98	proteomic profiling by mass spectrometry	26	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 98	proteomic profiling by mass spectrometry	26	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 98	proteomic profiling by mass spectrometry	26	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 98	proteomic profiling by mass spectrometry	26	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 98	proteomic profiling by mass spectrometry	26	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 99	proteomic profiling by mass spectrometry	27	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 99	proteomic profiling by mass spectrometry	27	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 99	proteomic profiling by mass spectrometry	27	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 99	proteomic profiling by mass spectrometry	27	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 99	proteomic profiling by mass spectrometry	27	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 99	proteomic profiling by mass spectrometry	27	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 99	proteomic profiling by mass spectrometry	27	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 99	proteomic profiling by mass spectrometry	27	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 99	proteomic profiling by mass spectrometry	27	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 99	proteomic profiling by mass spectrometry	27	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 100	proteomic profiling by mass spectrometry	28	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 100	proteomic profiling by mass spectrometry	28	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 100	proteomic profiling by mass spectrometry	28	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 100	proteomic profiling by mass spectrometry	28	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 100	proteomic profiling by mass spectrometry	28	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 100	proteomic profiling by mass spectrometry	28	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 100	proteomic profiling by mass spectrometry	28	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 100	proteomic profiling by mass spectrometry	28	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 100	proteomic profiling by mass spectrometry	28	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 100	proteomic profiling by mass spectrometry	28	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 101	proteomic profiling by mass spectrometry	29	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 101	proteomic profiling by mass spectrometry	29	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 101	proteomic profiling by mass spectrometry	29	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 101	proteomic profiling by mass spectrometry	29	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 101	proteomic profiling by mass spectrometry	29	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 101	proteomic profiling by mass spectrometry	29	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 101	proteomic profiling by mass spectrometry	29	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 101	proteomic profiling by mass spectrometry	29	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 101	proteomic profiling by mass spectrometry	29	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 101	proteomic profiling by mass spectrometry	29	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 102	proteomic profiling by mass spectrometry	30	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 102	proteomic profiling by mass spectrometry	30	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 102	proteomic profiling by mass spectrometry	30	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 102	proteomic profiling by mass spectrometry	30	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 102	proteomic profiling by mass spectrometry	30	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 102	proteomic profiling by mass spectrometry	30	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 102	proteomic profiling by mass spectrometry	30	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 102	proteomic profiling by mass spectrometry	30	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 102	proteomic profiling by mass spectrometry	30	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 102	proteomic profiling by mass spectrometry	30	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 103	proteomic profiling by mass spectrometry	31	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 103	proteomic profiling by mass spectrometry	31	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 103	proteomic profiling by mass spectrometry	31	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 103	proteomic profiling by mass spectrometry	31	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 103	proteomic profiling by mass spectrometry	31	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 103	proteomic profiling by mass spectrometry	31	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 103	proteomic profiling by mass spectrometry	31	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 103	proteomic profiling by mass spectrometry	31	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 103	proteomic profiling by mass spectrometry	31	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 103	proteomic profiling by mass spectrometry	31	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 104	proteomic profiling by mass spectrometry	32	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 104	proteomic profiling by mass spectrometry	32	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 104	proteomic profiling by mass spectrometry	32	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 104	proteomic profiling by mass spectrometry	32	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 104	proteomic profiling by mass spectrometry	32	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 104	proteomic profiling by mass spectrometry	32	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 104	proteomic profiling by mass spectrometry	32	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 104	proteomic profiling by mass spectrometry	32	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 104	proteomic profiling by mass spectrometry	32	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 104	proteomic profiling by mass spectrometry	32	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 105	proteomic profiling by mass spectrometry	33	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 105	proteomic profiling by mass spectrometry	33	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 105	proteomic profiling by mass spectrometry	33	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 105	proteomic profiling by mass spectrometry	33	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 105	proteomic profiling by mass spectrometry	33	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 105	proteomic profiling by mass spectrometry	33	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 105	proteomic profiling by mass spectrometry	33	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 105	proteomic profiling by mass spectrometry	33	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 105	proteomic profiling by mass spectrometry	33	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 105	proteomic profiling by mass spectrometry	33	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 106	proteomic profiling by mass spectrometry	34	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 106	proteomic profiling by mass spectrometry	34	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 106	proteomic profiling by mass spectrometry	34	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 106	proteomic profiling by mass spectrometry	34	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 106	proteomic profiling by mass spectrometry	34	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 106	proteomic profiling by mass spectrometry	34	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 106	proteomic profiling by mass spectrometry	34	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 106	proteomic profiling by mass spectrometry	34	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 106	proteomic profiling by mass spectrometry	34	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 106	proteomic profiling by mass spectrometry	34	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 107	proteomic profiling by mass spectrometry	35	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 107	proteomic profiling by mass spectrometry	35	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 107	proteomic profiling by mass spectrometry	35	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 107	proteomic profiling by mass spectrometry	35	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 107	proteomic profiling by mass spectrometry	35	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 107	proteomic profiling by mass spectrometry	35	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 107	proteomic profiling by mass spectrometry	35	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 107	proteomic profiling by mass spectrometry	35	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 107	proteomic profiling by mass spectrometry	35	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 107	proteomic profiling by mass spectrometry	35	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 108	proteomic profiling by mass spectrometry	36	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 108	proteomic profiling by mass spectrometry	36	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 108	proteomic profiling by mass spectrometry	36	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 108	proteomic profiling by mass spectrometry	36	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 108	proteomic profiling by mass spectrometry	36	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 108	proteomic profiling by mass spectrometry	36	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 108	proteomic profiling by mass spectrometry	36	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 108	proteomic profiling by mass spectrometry	36	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 108	proteomic profiling by mass spectrometry	36	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 108	proteomic profiling by mass spectrometry	36	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 109	proteomic profiling by mass spectrometry	37	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 109	proteomic profiling by mass spectrometry	37	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 109	proteomic profiling by mass spectrometry	37	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 109	proteomic profiling by mass spectrometry	37	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 109	proteomic profiling by mass spectrometry	37	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 109	proteomic profiling by mass spectrometry	37	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 109	proteomic profiling by mass spectrometry	37	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 109	proteomic profiling by mass spectrometry	37	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 109	proteomic profiling by mass spectrometry	37	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 109	proteomic profiling by mass spectrometry	37	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 110	proteomic profiling by mass spectrometry	38	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 110	proteomic profiling by mass spectrometry	38	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 110	proteomic profiling by mass spectrometry	38	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 110	proteomic profiling by mass spectrometry	38	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 110	proteomic profiling by mass spectrometry	38	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 110	proteomic profiling by mass spectrometry	38	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 110	proteomic profiling by mass spectrometry	38	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 110	proteomic profiling by mass spectrometry	38	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 110	proteomic profiling by mass spectrometry	38	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 110	proteomic profiling by mass spectrometry	38	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 111	proteomic profiling by mass spectrometry	39	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 111	proteomic profiling by mass spectrometry	39	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 111	proteomic profiling by mass spectrometry	39	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 111	proteomic profiling by mass spectrometry	39	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 111	proteomic profiling by mass spectrometry	39	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 111	proteomic profiling by mass spectrometry	39	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 111	proteomic profiling by mass spectrometry	39	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 111	proteomic profiling by mass spectrometry	39	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 111	proteomic profiling by mass spectrometry	39	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 111	proteomic profiling by mass spectrometry	39	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 112	proteomic profiling by mass spectrometry	40	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 112	proteomic profiling by mass spectrometry	40	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 112	proteomic profiling by mass spectrometry	40	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 112	proteomic profiling by mass spectrometry	40	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 112	proteomic profiling by mass spectrometry	40	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 112	proteomic profiling by mass spectrometry	40	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 112	proteomic profiling by mass spectrometry	40	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 112	proteomic profiling by mass spectrometry	40	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 112	proteomic profiling by mass spectrometry	40	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 112	proteomic profiling by mass spectrometry	40	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 113	proteomic profiling by mass spectrometry	41	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 113	proteomic profiling by mass spectrometry	41	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 113	proteomic profiling by mass spectrometry	41	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 113	proteomic profiling by mass spectrometry	41	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 113	proteomic profiling by mass spectrometry	41	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 113	proteomic profiling by mass spectrometry	41	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 113	proteomic profiling by mass spectrometry	41	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 113	proteomic profiling by mass spectrometry	41	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 113	proteomic profiling by mass spectrometry	41	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 113	proteomic profiling by mass spectrometry	41	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 114	proteomic profiling by mass spectrometry	42	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 114	proteomic profiling by mass spectrometry	42	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 114	proteomic profiling by mass spectrometry	42	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 114	proteomic profiling by mass spectrometry	42	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 114	proteomic profiling by mass spectrometry	42	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 114	proteomic profiling by mass spectrometry	42	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 114	proteomic profiling by mass spectrometry	42	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 114	proteomic profiling by mass spectrometry	42	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 114	proteomic profiling by mass spectrometry	42	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 114	proteomic profiling by mass spectrometry	42	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 115	proteomic profiling by mass spectrometry	43	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 115	proteomic profiling by mass spectrometry	43	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 115	proteomic profiling by mass spectrometry	43	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 115	proteomic profiling by mass spectrometry	43	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 115	proteomic profiling by mass spectrometry	43	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 115	proteomic profiling by mass spectrometry	43	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 115	proteomic profiling by mass spectrometry	43	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 115	proteomic profiling by mass spectrometry	43	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 115	proteomic profiling by mass spectrometry	43	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 115	proteomic profiling by mass spectrometry	43	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 116	proteomic profiling by mass spectrometry	44	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 116	proteomic profiling by mass spectrometry	44	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 116	proteomic profiling by mass spectrometry	44	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 116	proteomic profiling by mass spectrometry	44	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 116	proteomic profiling by mass spectrometry	44	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 116	proteomic profiling by mass spectrometry	44	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 116	proteomic profiling by mass spectrometry	44	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 116	proteomic profiling by mass spectrometry	44	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 116	proteomic profiling by mass spectrometry	44	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 116	proteomic profiling by mass spectrometry	44	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 117	proteomic profiling by mass spectrometry	45	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 117	proteomic profiling by mass spectrometry	45	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 117	proteomic profiling by mass spectrometry	45	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 117	proteomic profiling by mass spectrometry	45	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 117	proteomic profiling by mass spectrometry	45	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 117	proteomic profiling by mass spectrometry	45	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 117	proteomic profiling by mass spectrometry	45	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 117	proteomic profiling by mass spectrometry	45	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 117	proteomic profiling by mass spectrometry	45	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 117	proteomic profiling by mass spectrometry	45	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 118	proteomic profiling by mass spectrometry	46	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 118	proteomic profiling by mass spectrometry	46	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 118	proteomic profiling by mass spectrometry	46	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 118	proteomic profiling by mass spectrometry	46	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 118	proteomic profiling by mass spectrometry	46	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 118	proteomic profiling by mass spectrometry	46	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 118	proteomic profiling by mass spectrometry	46	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 118	proteomic profiling by mass spectrometry	46	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 118	proteomic profiling by mass spectrometry	46	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 118	proteomic profiling by mass spectrometry	46	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 119	proteomic profiling by mass spectrometry	47	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 119	proteomic profiling by mass spectrometry	47	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 119	proteomic profiling by mass spectrometry	47	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 119	proteomic profiling by mass spectrometry	47	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 119	proteomic profiling by mass spectrometry	47	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 119	proteomic profiling by mass spectrometry	47	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 119	proteomic profiling by mass spectrometry	47	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 119	proteomic profiling by mass spectrometry	47	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 119	proteomic profiling by mass spectrometry	47	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 119	proteomic profiling by mass spectrometry	47	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 120	proteomic profiling by mass spectrometry	48	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 120	proteomic profiling by mass spectrometry	48	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 120	proteomic profiling by mass spectrometry	48	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 120	proteomic profiling by mass spectrometry	48	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 120	proteomic profiling by mass spectrometry	48	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 120	proteomic profiling by mass spectrometry	48	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 120	proteomic profiling by mass spectrometry	48	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 120	proteomic profiling by mass spectrometry	48	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 120	proteomic profiling by mass spectrometry	48	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 120	proteomic profiling by mass spectrometry	48	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 121	proteomic profiling by mass spectrometry	49	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 121	proteomic profiling by mass spectrometry	49	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 121	proteomic profiling by mass spectrometry	49	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 121	proteomic profiling by mass spectrometry	49	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 121	proteomic profiling by mass spectrometry	49	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 121	proteomic profiling by mass spectrometry	49	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 121	proteomic profiling by mass spectrometry	49	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 121	proteomic profiling by mass spectrometry	49	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 121	proteomic profiling by mass spectrometry	49	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 121	proteomic profiling by mass spectrometry	49	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 122	proteomic profiling by mass spectrometry	50	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 122	proteomic profiling by mass spectrometry	50	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 122	proteomic profiling by mass spectrometry	50	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 122	proteomic profiling by mass spectrometry	50	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 122	proteomic profiling by mass spectrometry	50	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 122	proteomic profiling by mass spectrometry	50	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 122	proteomic profiling by mass spectrometry	50	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 122	proteomic profiling by mass spectrometry	50	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 122	proteomic profiling by mass spectrometry	50	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 122	proteomic profiling by mass spectrometry	50	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 123	proteomic profiling by mass spectrometry	51	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 123	proteomic profiling by mass spectrometry	51	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 123	proteomic profiling by mass spectrometry	51	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 123	proteomic profiling by mass spectrometry	51	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 123	proteomic profiling by mass spectrometry	51	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 123	proteomic profiling by mass spectrometry	51	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 123	proteomic profiling by mass spectrometry	51	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 123	proteomic profiling by mass spectrometry	51	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 123	proteomic profiling by mass spectrometry	51	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 123	proteomic profiling by mass spectrometry	51	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 124	proteomic profiling by mass spectrometry	52	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 124	proteomic profiling by mass spectrometry	52	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 124	proteomic profiling by mass spectrometry	52	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 124	proteomic profiling by mass spectrometry	52	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 124	proteomic profiling by mass spectrometry	52	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 124	proteomic profiling by mass spectrometry	52	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 124	proteomic profiling by mass spectrometry	52	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 124	proteomic profiling by mass spectrometry	52	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 124	proteomic profiling by mass spectrometry	52	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 124	proteomic profiling by mass spectrometry	52	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 125	proteomic profiling by mass spectrometry	53	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 125	proteomic profiling by mass spectrometry	53	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 125	proteomic profiling by mass spectrometry	53	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 125	proteomic profiling by mass spectrometry	53	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 125	proteomic profiling by mass spectrometry	53	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 125	proteomic profiling by mass spectrometry	53	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 125	proteomic profiling by mass spectrometry	53	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 125	proteomic profiling by mass spectrometry	53	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 125	proteomic profiling by mass spectrometry	53	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 125	proteomic profiling by mass spectrometry	53	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 126	proteomic profiling by mass spectrometry	54	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 126	proteomic profiling by mass spectrometry	54	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 126	proteomic profiling by mass spectrometry	54	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 126	proteomic profiling by mass spectrometry	54	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 126	proteomic profiling by mass spectrometry	54	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 126	proteomic profiling by mass spectrometry	54	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 126	proteomic profiling by mass spectrometry	54	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 126	proteomic profiling by mass spectrometry	54	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 126	proteomic profiling by mass spectrometry	54	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 126	proteomic profiling by mass spectrometry	54	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 127	proteomic profiling by mass spectrometry	55	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 127	proteomic profiling by mass spectrometry	55	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 127	proteomic profiling by mass spectrometry	55	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 127	proteomic profiling by mass spectrometry	55	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 127	proteomic profiling by mass spectrometry	55	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 127	proteomic profiling by mass spectrometry	55	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 127	proteomic profiling by mass spectrometry	55	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 127	proteomic profiling by mass spectrometry	55	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 127	proteomic profiling by mass spectrometry	55	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 127	proteomic profiling by mass spectrometry	55	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 128	proteomic profiling by mass spectrometry	56	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 128	proteomic profiling by mass spectrometry	56	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 128	proteomic profiling by mass spectrometry	56	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 128	proteomic profiling by mass spectrometry	56	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 128	proteomic profiling by mass spectrometry	56	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 128	proteomic profiling by mass spectrometry	56	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 128	proteomic profiling by mass spectrometry	56	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 128	proteomic profiling by mass spectrometry	56	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 128	proteomic profiling by mass spectrometry	56	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 128	proteomic profiling by mass spectrometry	56	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 129	proteomic profiling by mass spectrometry	57	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 129	proteomic profiling by mass spectrometry	57	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 129	proteomic profiling by mass spectrometry	57	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 129	proteomic profiling by mass spectrometry	57	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 129	proteomic profiling by mass spectrometry	57	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 129	proteomic profiling by mass spectrometry	57	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 129	proteomic profiling by mass spectrometry	57	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 129	proteomic profiling by mass spectrometry	57	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 129	proteomic profiling by mass spectrometry	57	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 129	proteomic profiling by mass spectrometry	57	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 130	proteomic profiling by mass spectrometry	58	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 130	proteomic profiling by mass spectrometry	58	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 130	proteomic profiling by mass spectrometry	58	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 130	proteomic profiling by mass spectrometry	58	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 130	proteomic profiling by mass spectrometry	58	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 130	proteomic profiling by mass spectrometry	58	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 130	proteomic profiling by mass spectrometry	58	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 130	proteomic profiling by mass spectrometry	58	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 130	proteomic profiling by mass spectrometry	58	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 130	proteomic profiling by mass spectrometry	58	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 131	proteomic profiling by mass spectrometry	59	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 131	proteomic profiling by mass spectrometry	59	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 131	proteomic profiling by mass spectrometry	59	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 131	proteomic profiling by mass spectrometry	59	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 131	proteomic profiling by mass spectrometry	59	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 131	proteomic profiling by mass spectrometry	59	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 131	proteomic profiling by mass spectrometry	59	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 131	proteomic profiling by mass spectrometry	59	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 131	proteomic profiling by mass spectrometry	59	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 131	proteomic profiling by mass spectrometry	59	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 132	proteomic profiling by mass spectrometry	60	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 132	proteomic profiling by mass spectrometry	60	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 132	proteomic profiling by mass spectrometry	60	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 132	proteomic profiling by mass spectrometry	60	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 132	proteomic profiling by mass spectrometry	60	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 132	proteomic profiling by mass spectrometry	60	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 132	proteomic profiling by mass spectrometry	60	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 132	proteomic profiling by mass spectrometry	60	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 132	proteomic profiling by mass spectrometry	60	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 132	proteomic profiling by mass spectrometry	60	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 133	proteomic profiling by mass spectrometry	61	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 133	proteomic profiling by mass spectrometry	61	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 133	proteomic profiling by mass spectrometry	61	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 133	proteomic profiling by mass spectrometry	61	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 133	proteomic profiling by mass spectrometry	61	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 133	proteomic profiling by mass spectrometry	61	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 133	proteomic profiling by mass spectrometry	61	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 133	proteomic profiling by mass spectrometry	61	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 133	proteomic profiling by mass spectrometry	61	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 133	proteomic profiling by mass spectrometry	61	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 134	proteomic profiling by mass spectrometry	62	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 134	proteomic profiling by mass spectrometry	62	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 134	proteomic profiling by mass spectrometry	62	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 134	proteomic profiling by mass spectrometry	62	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 134	proteomic profiling by mass spectrometry	62	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 134	proteomic profiling by mass spectrometry	62	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 134	proteomic profiling by mass spectrometry	62	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 134	proteomic profiling by mass spectrometry	62	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 134	proteomic profiling by mass spectrometry	62	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 134	proteomic profiling by mass spectrometry	62	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 135	proteomic profiling by mass spectrometry	63	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 135	proteomic profiling by mass spectrometry	63	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 135	proteomic profiling by mass spectrometry	63	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 135	proteomic profiling by mass spectrometry	63	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 135	proteomic profiling by mass spectrometry	63	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 135	proteomic profiling by mass spectrometry	63	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 135	proteomic profiling by mass spectrometry	63	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 135	proteomic profiling by mass spectrometry	63	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 135	proteomic profiling by mass spectrometry	63	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 135	proteomic profiling by mass spectrometry	63	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 136	proteomic profiling by mass spectrometry	64	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 136	proteomic profiling by mass spectrometry	64	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 136	proteomic profiling by mass spectrometry	64	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 136	proteomic profiling by mass spectrometry	64	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 136	proteomic profiling by mass spectrometry	64	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 136	proteomic profiling by mass spectrometry	64	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 136	proteomic profiling by mass spectrometry	64	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 136	proteomic profiling by mass spectrometry	64	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 136	proteomic profiling by mass spectrometry	64	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 136	proteomic profiling by mass spectrometry	64	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 137	proteomic profiling by mass spectrometry	65	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 137	proteomic profiling by mass spectrometry	65	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 137	proteomic profiling by mass spectrometry	65	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 137	proteomic profiling by mass spectrometry	65	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 137	proteomic profiling by mass spectrometry	65	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 137	proteomic profiling by mass spectrometry	65	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 137	proteomic profiling by mass spectrometry	65	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 137	proteomic profiling by mass spectrometry	65	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 137	proteomic profiling by mass spectrometry	65	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 137	proteomic profiling by mass spectrometry	65	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 138	proteomic profiling by mass spectrometry	66	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 138	proteomic profiling by mass spectrometry	66	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 138	proteomic profiling by mass spectrometry	66	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 138	proteomic profiling by mass spectrometry	66	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 138	proteomic profiling by mass spectrometry	66	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 138	proteomic profiling by mass spectrometry	66	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 138	proteomic profiling by mass spectrometry	66	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 138	proteomic profiling by mass spectrometry	66	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 138	proteomic profiling by mass spectrometry	66	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 138	proteomic profiling by mass spectrometry	66	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 139	proteomic profiling by mass spectrometry	67	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 139	proteomic profiling by mass spectrometry	67	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 139	proteomic profiling by mass spectrometry	67	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 139	proteomic profiling by mass spectrometry	67	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 139	proteomic profiling by mass spectrometry	67	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 139	proteomic profiling by mass spectrometry	67	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 139	proteomic profiling by mass spectrometry	67	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 139	proteomic profiling by mass spectrometry	67	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 139	proteomic profiling by mass spectrometry	67	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 139	proteomic profiling by mass spectrometry	67	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 140	proteomic profiling by mass spectrometry	68	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 140	proteomic profiling by mass spectrometry	68	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 140	proteomic profiling by mass spectrometry	68	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 140	proteomic profiling by mass spectrometry	68	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 140	proteomic profiling by mass spectrometry	68	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 140	proteomic profiling by mass spectrometry	68	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 140	proteomic profiling by mass spectrometry	68	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 140	proteomic profiling by mass spectrometry	68	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 140	proteomic profiling by mass spectrometry	68	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 140	proteomic profiling by mass spectrometry	68	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 141	proteomic profiling by mass spectrometry	69	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 141	proteomic profiling by mass spectrometry	69	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 141	proteomic profiling by mass spectrometry	69	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 141	proteomic profiling by mass spectrometry	69	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 141	proteomic profiling by mass spectrometry	69	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 141	proteomic profiling by mass spectrometry	69	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 141	proteomic profiling by mass spectrometry	69	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 141	proteomic profiling by mass spectrometry	69	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 141	proteomic profiling by mass spectrometry	69	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 141	proteomic profiling by mass spectrometry	69	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 142	proteomic profiling by mass spectrometry	70	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 142	proteomic profiling by mass spectrometry	70	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 142	proteomic profiling by mass spectrometry	70	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 142	proteomic profiling by mass spectrometry	70	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 142	proteomic profiling by mass spectrometry	70	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 142	proteomic profiling by mass spectrometry	70	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 142	proteomic profiling by mass spectrometry	70	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 142	proteomic profiling by mass spectrometry	70	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 142	proteomic profiling by mass spectrometry	70	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 142	proteomic profiling by mass spectrometry	70	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 143	proteomic profiling by mass spectrometry	71	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 143	proteomic profiling by mass spectrometry	71	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 143	proteomic profiling by mass spectrometry	71	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 143	proteomic profiling by mass spectrometry	71	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 143	proteomic profiling by mass spectrometry	71	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 143	proteomic profiling by mass spectrometry	71	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 143	proteomic profiling by mass spectrometry	71	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 143	proteomic profiling by mass spectrometry	71	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 143	proteomic profiling by mass spectrometry	71	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 143	proteomic profiling by mass spectrometry	71	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 11	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_058	tissue	run 144	proteomic profiling by mass spectrometry	72	TMT126	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 12	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_058	tissue	run 144	proteomic profiling by mass spectrometry	72	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 13	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_059	tissue	run 144	proteomic profiling by mass spectrometry	72	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 14	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_059	tissue	run 144	proteomic profiling by mass spectrometry	72	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 15	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_061	tissue	run 144	proteomic profiling by mass spectrometry	72	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 16	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_040	tissue	run 144	proteomic profiling by mass spectrometry	72	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 17	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_040	tissue	run 144	proteomic profiling by mass spectrometry	72	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 18	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_056	tissue	run 144	proteomic profiling by mass spectrometry	72	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 19	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_056	tissue	run 144	proteomic profiling by mass spectrometry	72	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 20	Homo sapiens	blood plasma	2	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS2	tissue	run 144	proteomic profiling by mass spectrometry	72	TMT131	LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set2_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 145	proteomic profiling by mass spectrometry	1	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 145	proteomic profiling by mass spectrometry	1	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 145	proteomic profiling by mass spectrometry	1	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 145	proteomic profiling by mass spectrometry	1	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 145	proteomic profiling by mass spectrometry	1	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 145	proteomic profiling by mass spectrometry	1	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 145	proteomic profiling by mass spectrometry	1	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 145	proteomic profiling by mass spectrometry	1	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 145	proteomic profiling by mass spectrometry	1	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 145	proteomic profiling by mass spectrometry	1	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 146	proteomic profiling by mass spectrometry	2	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 146	proteomic profiling by mass spectrometry	2	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 146	proteomic profiling by mass spectrometry	2	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 146	proteomic profiling by mass spectrometry	2	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 146	proteomic profiling by mass spectrometry	2	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 146	proteomic profiling by mass spectrometry	2	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 146	proteomic profiling by mass spectrometry	2	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 146	proteomic profiling by mass spectrometry	2	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 146	proteomic profiling by mass spectrometry	2	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 146	proteomic profiling by mass spectrometry	2	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 147	proteomic profiling by mass spectrometry	3	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 147	proteomic profiling by mass spectrometry	3	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 147	proteomic profiling by mass spectrometry	3	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 147	proteomic profiling by mass spectrometry	3	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 147	proteomic profiling by mass spectrometry	3	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 147	proteomic profiling by mass spectrometry	3	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 147	proteomic profiling by mass spectrometry	3	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 147	proteomic profiling by mass spectrometry	3	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 147	proteomic profiling by mass spectrometry	3	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 147	proteomic profiling by mass spectrometry	3	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 148	proteomic profiling by mass spectrometry	4	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 148	proteomic profiling by mass spectrometry	4	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 148	proteomic profiling by mass spectrometry	4	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 148	proteomic profiling by mass spectrometry	4	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 148	proteomic profiling by mass spectrometry	4	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 148	proteomic profiling by mass spectrometry	4	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 148	proteomic profiling by mass spectrometry	4	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 148	proteomic profiling by mass spectrometry	4	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 148	proteomic profiling by mass spectrometry	4	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 148	proteomic profiling by mass spectrometry	4	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 149	proteomic profiling by mass spectrometry	5	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 149	proteomic profiling by mass spectrometry	5	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 149	proteomic profiling by mass spectrometry	5	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 149	proteomic profiling by mass spectrometry	5	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 149	proteomic profiling by mass spectrometry	5	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 149	proteomic profiling by mass spectrometry	5	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 149	proteomic profiling by mass spectrometry	5	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 149	proteomic profiling by mass spectrometry	5	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 149	proteomic profiling by mass spectrometry	5	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 149	proteomic profiling by mass spectrometry	5	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 150	proteomic profiling by mass spectrometry	6	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 150	proteomic profiling by mass spectrometry	6	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 150	proteomic profiling by mass spectrometry	6	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 150	proteomic profiling by mass spectrometry	6	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 150	proteomic profiling by mass spectrometry	6	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 150	proteomic profiling by mass spectrometry	6	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 150	proteomic profiling by mass spectrometry	6	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 150	proteomic profiling by mass spectrometry	6	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 150	proteomic profiling by mass spectrometry	6	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 150	proteomic profiling by mass spectrometry	6	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 151	proteomic profiling by mass spectrometry	7	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 151	proteomic profiling by mass spectrometry	7	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 151	proteomic profiling by mass spectrometry	7	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 151	proteomic profiling by mass spectrometry	7	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 151	proteomic profiling by mass spectrometry	7	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 151	proteomic profiling by mass spectrometry	7	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 151	proteomic profiling by mass spectrometry	7	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 151	proteomic profiling by mass spectrometry	7	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 151	proteomic profiling by mass spectrometry	7	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 151	proteomic profiling by mass spectrometry	7	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 152	proteomic profiling by mass spectrometry	8	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 152	proteomic profiling by mass spectrometry	8	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 152	proteomic profiling by mass spectrometry	8	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 152	proteomic profiling by mass spectrometry	8	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 152	proteomic profiling by mass spectrometry	8	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 152	proteomic profiling by mass spectrometry	8	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 152	proteomic profiling by mass spectrometry	8	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 152	proteomic profiling by mass spectrometry	8	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 152	proteomic profiling by mass spectrometry	8	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 152	proteomic profiling by mass spectrometry	8	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 153	proteomic profiling by mass spectrometry	9	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 153	proteomic profiling by mass spectrometry	9	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 153	proteomic profiling by mass spectrometry	9	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 153	proteomic profiling by mass spectrometry	9	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 153	proteomic profiling by mass spectrometry	9	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 153	proteomic profiling by mass spectrometry	9	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 153	proteomic profiling by mass spectrometry	9	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 153	proteomic profiling by mass spectrometry	9	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 153	proteomic profiling by mass spectrometry	9	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 153	proteomic profiling by mass spectrometry	9	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 154	proteomic profiling by mass spectrometry	10	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 154	proteomic profiling by mass spectrometry	10	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 154	proteomic profiling by mass spectrometry	10	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 154	proteomic profiling by mass spectrometry	10	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 154	proteomic profiling by mass spectrometry	10	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 154	proteomic profiling by mass spectrometry	10	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 154	proteomic profiling by mass spectrometry	10	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 154	proteomic profiling by mass spectrometry	10	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 154	proteomic profiling by mass spectrometry	10	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 154	proteomic profiling by mass spectrometry	10	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 155	proteomic profiling by mass spectrometry	11	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 155	proteomic profiling by mass spectrometry	11	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 155	proteomic profiling by mass spectrometry	11	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 155	proteomic profiling by mass spectrometry	11	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 155	proteomic profiling by mass spectrometry	11	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 155	proteomic profiling by mass spectrometry	11	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 155	proteomic profiling by mass spectrometry	11	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 155	proteomic profiling by mass spectrometry	11	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 155	proteomic profiling by mass spectrometry	11	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 155	proteomic profiling by mass spectrometry	11	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 156	proteomic profiling by mass spectrometry	12	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 156	proteomic profiling by mass spectrometry	12	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 156	proteomic profiling by mass spectrometry	12	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 156	proteomic profiling by mass spectrometry	12	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 156	proteomic profiling by mass spectrometry	12	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 156	proteomic profiling by mass spectrometry	12	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 156	proteomic profiling by mass spectrometry	12	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 156	proteomic profiling by mass spectrometry	12	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 156	proteomic profiling by mass spectrometry	12	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 156	proteomic profiling by mass spectrometry	12	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 157	proteomic profiling by mass spectrometry	13	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 157	proteomic profiling by mass spectrometry	13	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 157	proteomic profiling by mass spectrometry	13	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 157	proteomic profiling by mass spectrometry	13	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 157	proteomic profiling by mass spectrometry	13	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 157	proteomic profiling by mass spectrometry	13	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 157	proteomic profiling by mass spectrometry	13	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 157	proteomic profiling by mass spectrometry	13	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 157	proteomic profiling by mass spectrometry	13	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 157	proteomic profiling by mass spectrometry	13	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 158	proteomic profiling by mass spectrometry	14	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 158	proteomic profiling by mass spectrometry	14	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 158	proteomic profiling by mass spectrometry	14	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 158	proteomic profiling by mass spectrometry	14	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 158	proteomic profiling by mass spectrometry	14	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 158	proteomic profiling by mass spectrometry	14	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 158	proteomic profiling by mass spectrometry	14	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 158	proteomic profiling by mass spectrometry	14	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 158	proteomic profiling by mass spectrometry	14	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 158	proteomic profiling by mass spectrometry	14	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 159	proteomic profiling by mass spectrometry	15	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 159	proteomic profiling by mass spectrometry	15	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 159	proteomic profiling by mass spectrometry	15	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 159	proteomic profiling by mass spectrometry	15	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 159	proteomic profiling by mass spectrometry	15	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 159	proteomic profiling by mass spectrometry	15	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 159	proteomic profiling by mass spectrometry	15	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 159	proteomic profiling by mass spectrometry	15	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 159	proteomic profiling by mass spectrometry	15	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 159	proteomic profiling by mass spectrometry	15	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 160	proteomic profiling by mass spectrometry	16	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 160	proteomic profiling by mass spectrometry	16	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 160	proteomic profiling by mass spectrometry	16	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 160	proteomic profiling by mass spectrometry	16	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 160	proteomic profiling by mass spectrometry	16	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 160	proteomic profiling by mass spectrometry	16	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 160	proteomic profiling by mass spectrometry	16	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 160	proteomic profiling by mass spectrometry	16	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 160	proteomic profiling by mass spectrometry	16	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 160	proteomic profiling by mass spectrometry	16	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 161	proteomic profiling by mass spectrometry	17	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 161	proteomic profiling by mass spectrometry	17	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 161	proteomic profiling by mass spectrometry	17	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 161	proteomic profiling by mass spectrometry	17	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 161	proteomic profiling by mass spectrometry	17	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 161	proteomic profiling by mass spectrometry	17	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 161	proteomic profiling by mass spectrometry	17	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 161	proteomic profiling by mass spectrometry	17	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 161	proteomic profiling by mass spectrometry	17	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 161	proteomic profiling by mass spectrometry	17	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 162	proteomic profiling by mass spectrometry	18	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 162	proteomic profiling by mass spectrometry	18	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 162	proteomic profiling by mass spectrometry	18	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 162	proteomic profiling by mass spectrometry	18	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 162	proteomic profiling by mass spectrometry	18	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 162	proteomic profiling by mass spectrometry	18	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 162	proteomic profiling by mass spectrometry	18	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 162	proteomic profiling by mass spectrometry	18	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 162	proteomic profiling by mass spectrometry	18	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 162	proteomic profiling by mass spectrometry	18	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 163	proteomic profiling by mass spectrometry	19	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 163	proteomic profiling by mass spectrometry	19	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 163	proteomic profiling by mass spectrometry	19	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 163	proteomic profiling by mass spectrometry	19	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 163	proteomic profiling by mass spectrometry	19	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 163	proteomic profiling by mass spectrometry	19	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 163	proteomic profiling by mass spectrometry	19	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 163	proteomic profiling by mass spectrometry	19	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 163	proteomic profiling by mass spectrometry	19	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 163	proteomic profiling by mass spectrometry	19	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 164	proteomic profiling by mass spectrometry	20	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 164	proteomic profiling by mass spectrometry	20	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 164	proteomic profiling by mass spectrometry	20	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 164	proteomic profiling by mass spectrometry	20	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 164	proteomic profiling by mass spectrometry	20	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 164	proteomic profiling by mass spectrometry	20	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 164	proteomic profiling by mass spectrometry	20	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 164	proteomic profiling by mass spectrometry	20	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 164	proteomic profiling by mass spectrometry	20	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 164	proteomic profiling by mass spectrometry	20	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 165	proteomic profiling by mass spectrometry	21	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 165	proteomic profiling by mass spectrometry	21	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 165	proteomic profiling by mass spectrometry	21	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 165	proteomic profiling by mass spectrometry	21	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 165	proteomic profiling by mass spectrometry	21	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 165	proteomic profiling by mass spectrometry	21	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 165	proteomic profiling by mass spectrometry	21	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 165	proteomic profiling by mass spectrometry	21	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 165	proteomic profiling by mass spectrometry	21	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 165	proteomic profiling by mass spectrometry	21	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 166	proteomic profiling by mass spectrometry	22	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 166	proteomic profiling by mass spectrometry	22	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 166	proteomic profiling by mass spectrometry	22	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 166	proteomic profiling by mass spectrometry	22	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 166	proteomic profiling by mass spectrometry	22	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 166	proteomic profiling by mass spectrometry	22	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 166	proteomic profiling by mass spectrometry	22	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 166	proteomic profiling by mass spectrometry	22	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 166	proteomic profiling by mass spectrometry	22	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 166	proteomic profiling by mass spectrometry	22	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 167	proteomic profiling by mass spectrometry	23	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 167	proteomic profiling by mass spectrometry	23	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 167	proteomic profiling by mass spectrometry	23	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 167	proteomic profiling by mass spectrometry	23	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 167	proteomic profiling by mass spectrometry	23	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 167	proteomic profiling by mass spectrometry	23	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 167	proteomic profiling by mass spectrometry	23	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 167	proteomic profiling by mass spectrometry	23	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 167	proteomic profiling by mass spectrometry	23	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 167	proteomic profiling by mass spectrometry	23	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 168	proteomic profiling by mass spectrometry	24	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 168	proteomic profiling by mass spectrometry	24	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 168	proteomic profiling by mass spectrometry	24	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 168	proteomic profiling by mass spectrometry	24	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 168	proteomic profiling by mass spectrometry	24	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 168	proteomic profiling by mass spectrometry	24	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 168	proteomic profiling by mass spectrometry	24	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 168	proteomic profiling by mass spectrometry	24	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 168	proteomic profiling by mass spectrometry	24	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 168	proteomic profiling by mass spectrometry	24	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 169	proteomic profiling by mass spectrometry	25	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 169	proteomic profiling by mass spectrometry	25	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 169	proteomic profiling by mass spectrometry	25	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 169	proteomic profiling by mass spectrometry	25	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 169	proteomic profiling by mass spectrometry	25	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 169	proteomic profiling by mass spectrometry	25	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 169	proteomic profiling by mass spectrometry	25	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 169	proteomic profiling by mass spectrometry	25	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 169	proteomic profiling by mass spectrometry	25	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 169	proteomic profiling by mass spectrometry	25	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 170	proteomic profiling by mass spectrometry	26	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 170	proteomic profiling by mass spectrometry	26	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 170	proteomic profiling by mass spectrometry	26	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 170	proteomic profiling by mass spectrometry	26	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 170	proteomic profiling by mass spectrometry	26	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 170	proteomic profiling by mass spectrometry	26	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 170	proteomic profiling by mass spectrometry	26	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 170	proteomic profiling by mass spectrometry	26	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 170	proteomic profiling by mass spectrometry	26	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 170	proteomic profiling by mass spectrometry	26	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 171	proteomic profiling by mass spectrometry	27	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 171	proteomic profiling by mass spectrometry	27	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 171	proteomic profiling by mass spectrometry	27	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 171	proteomic profiling by mass spectrometry	27	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 171	proteomic profiling by mass spectrometry	27	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 171	proteomic profiling by mass spectrometry	27	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 171	proteomic profiling by mass spectrometry	27	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 171	proteomic profiling by mass spectrometry	27	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 171	proteomic profiling by mass spectrometry	27	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 171	proteomic profiling by mass spectrometry	27	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 172	proteomic profiling by mass spectrometry	28	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 172	proteomic profiling by mass spectrometry	28	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 172	proteomic profiling by mass spectrometry	28	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 172	proteomic profiling by mass spectrometry	28	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 172	proteomic profiling by mass spectrometry	28	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 172	proteomic profiling by mass spectrometry	28	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 172	proteomic profiling by mass spectrometry	28	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 172	proteomic profiling by mass spectrometry	28	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 172	proteomic profiling by mass spectrometry	28	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 172	proteomic profiling by mass spectrometry	28	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 173	proteomic profiling by mass spectrometry	29	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 173	proteomic profiling by mass spectrometry	29	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 173	proteomic profiling by mass spectrometry	29	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 173	proteomic profiling by mass spectrometry	29	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 173	proteomic profiling by mass spectrometry	29	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 173	proteomic profiling by mass spectrometry	29	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 173	proteomic profiling by mass spectrometry	29	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 173	proteomic profiling by mass spectrometry	29	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 173	proteomic profiling by mass spectrometry	29	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 173	proteomic profiling by mass spectrometry	29	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 174	proteomic profiling by mass spectrometry	30	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 174	proteomic profiling by mass spectrometry	30	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 174	proteomic profiling by mass spectrometry	30	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 174	proteomic profiling by mass spectrometry	30	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 174	proteomic profiling by mass spectrometry	30	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 174	proteomic profiling by mass spectrometry	30	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 174	proteomic profiling by mass spectrometry	30	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 174	proteomic profiling by mass spectrometry	30	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 174	proteomic profiling by mass spectrometry	30	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 174	proteomic profiling by mass spectrometry	30	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 175	proteomic profiling by mass spectrometry	31	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 175	proteomic profiling by mass spectrometry	31	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 175	proteomic profiling by mass spectrometry	31	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 175	proteomic profiling by mass spectrometry	31	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 175	proteomic profiling by mass spectrometry	31	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 175	proteomic profiling by mass spectrometry	31	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 175	proteomic profiling by mass spectrometry	31	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 175	proteomic profiling by mass spectrometry	31	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 175	proteomic profiling by mass spectrometry	31	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 175	proteomic profiling by mass spectrometry	31	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 176	proteomic profiling by mass spectrometry	32	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 176	proteomic profiling by mass spectrometry	32	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 176	proteomic profiling by mass spectrometry	32	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 176	proteomic profiling by mass spectrometry	32	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 176	proteomic profiling by mass spectrometry	32	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 176	proteomic profiling by mass spectrometry	32	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 176	proteomic profiling by mass spectrometry	32	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 176	proteomic profiling by mass spectrometry	32	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 176	proteomic profiling by mass spectrometry	32	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 176	proteomic profiling by mass spectrometry	32	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 177	proteomic profiling by mass spectrometry	33	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 177	proteomic profiling by mass spectrometry	33	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 177	proteomic profiling by mass spectrometry	33	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 177	proteomic profiling by mass spectrometry	33	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 177	proteomic profiling by mass spectrometry	33	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 177	proteomic profiling by mass spectrometry	33	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 177	proteomic profiling by mass spectrometry	33	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 177	proteomic profiling by mass spectrometry	33	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 177	proteomic profiling by mass spectrometry	33	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 177	proteomic profiling by mass spectrometry	33	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 178	proteomic profiling by mass spectrometry	34	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 178	proteomic profiling by mass spectrometry	34	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 178	proteomic profiling by mass spectrometry	34	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 178	proteomic profiling by mass spectrometry	34	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 178	proteomic profiling by mass spectrometry	34	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 178	proteomic profiling by mass spectrometry	34	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 178	proteomic profiling by mass spectrometry	34	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 178	proteomic profiling by mass spectrometry	34	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 178	proteomic profiling by mass spectrometry	34	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 178	proteomic profiling by mass spectrometry	34	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 179	proteomic profiling by mass spectrometry	35	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 179	proteomic profiling by mass spectrometry	35	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 179	proteomic profiling by mass spectrometry	35	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 179	proteomic profiling by mass spectrometry	35	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 179	proteomic profiling by mass spectrometry	35	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 179	proteomic profiling by mass spectrometry	35	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 179	proteomic profiling by mass spectrometry	35	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 179	proteomic profiling by mass spectrometry	35	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 179	proteomic profiling by mass spectrometry	35	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 179	proteomic profiling by mass spectrometry	35	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 180	proteomic profiling by mass spectrometry	36	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 180	proteomic profiling by mass spectrometry	36	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 180	proteomic profiling by mass spectrometry	36	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 180	proteomic profiling by mass spectrometry	36	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 180	proteomic profiling by mass spectrometry	36	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 180	proteomic profiling by mass spectrometry	36	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 180	proteomic profiling by mass spectrometry	36	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 180	proteomic profiling by mass spectrometry	36	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 180	proteomic profiling by mass spectrometry	36	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 180	proteomic profiling by mass spectrometry	36	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 181	proteomic profiling by mass spectrometry	37	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 181	proteomic profiling by mass spectrometry	37	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 181	proteomic profiling by mass spectrometry	37	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 181	proteomic profiling by mass spectrometry	37	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 181	proteomic profiling by mass spectrometry	37	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 181	proteomic profiling by mass spectrometry	37	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 181	proteomic profiling by mass spectrometry	37	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 181	proteomic profiling by mass spectrometry	37	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 181	proteomic profiling by mass spectrometry	37	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 181	proteomic profiling by mass spectrometry	37	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 182	proteomic profiling by mass spectrometry	38	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 182	proteomic profiling by mass spectrometry	38	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 182	proteomic profiling by mass spectrometry	38	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 182	proteomic profiling by mass spectrometry	38	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 182	proteomic profiling by mass spectrometry	38	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 182	proteomic profiling by mass spectrometry	38	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 182	proteomic profiling by mass spectrometry	38	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 182	proteomic profiling by mass spectrometry	38	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 182	proteomic profiling by mass spectrometry	38	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 182	proteomic profiling by mass spectrometry	38	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 183	proteomic profiling by mass spectrometry	39	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 183	proteomic profiling by mass spectrometry	39	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 183	proteomic profiling by mass spectrometry	39	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 183	proteomic profiling by mass spectrometry	39	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 183	proteomic profiling by mass spectrometry	39	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 183	proteomic profiling by mass spectrometry	39	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 183	proteomic profiling by mass spectrometry	39	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 183	proteomic profiling by mass spectrometry	39	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 183	proteomic profiling by mass spectrometry	39	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 183	proteomic profiling by mass spectrometry	39	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 184	proteomic profiling by mass spectrometry	40	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 184	proteomic profiling by mass spectrometry	40	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 184	proteomic profiling by mass spectrometry	40	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 184	proteomic profiling by mass spectrometry	40	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 184	proteomic profiling by mass spectrometry	40	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 184	proteomic profiling by mass spectrometry	40	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 184	proteomic profiling by mass spectrometry	40	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 184	proteomic profiling by mass spectrometry	40	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 184	proteomic profiling by mass spectrometry	40	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 184	proteomic profiling by mass spectrometry	40	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 185	proteomic profiling by mass spectrometry	41	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 185	proteomic profiling by mass spectrometry	41	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 185	proteomic profiling by mass spectrometry	41	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 185	proteomic profiling by mass spectrometry	41	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 185	proteomic profiling by mass spectrometry	41	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 185	proteomic profiling by mass spectrometry	41	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 185	proteomic profiling by mass spectrometry	41	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 185	proteomic profiling by mass spectrometry	41	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 185	proteomic profiling by mass spectrometry	41	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 185	proteomic profiling by mass spectrometry	41	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 186	proteomic profiling by mass spectrometry	42	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 186	proteomic profiling by mass spectrometry	42	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 186	proteomic profiling by mass spectrometry	42	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 186	proteomic profiling by mass spectrometry	42	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 186	proteomic profiling by mass spectrometry	42	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 186	proteomic profiling by mass spectrometry	42	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 186	proteomic profiling by mass spectrometry	42	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 186	proteomic profiling by mass spectrometry	42	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 186	proteomic profiling by mass spectrometry	42	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 186	proteomic profiling by mass spectrometry	42	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 187	proteomic profiling by mass spectrometry	43	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 187	proteomic profiling by mass spectrometry	43	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 187	proteomic profiling by mass spectrometry	43	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 187	proteomic profiling by mass spectrometry	43	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 187	proteomic profiling by mass spectrometry	43	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 187	proteomic profiling by mass spectrometry	43	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 187	proteomic profiling by mass spectrometry	43	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 187	proteomic profiling by mass spectrometry	43	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 187	proteomic profiling by mass spectrometry	43	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 187	proteomic profiling by mass spectrometry	43	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 188	proteomic profiling by mass spectrometry	44	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 188	proteomic profiling by mass spectrometry	44	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 188	proteomic profiling by mass spectrometry	44	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 188	proteomic profiling by mass spectrometry	44	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 188	proteomic profiling by mass spectrometry	44	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 188	proteomic profiling by mass spectrometry	44	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 188	proteomic profiling by mass spectrometry	44	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 188	proteomic profiling by mass spectrometry	44	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 188	proteomic profiling by mass spectrometry	44	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 188	proteomic profiling by mass spectrometry	44	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 189	proteomic profiling by mass spectrometry	45	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 189	proteomic profiling by mass spectrometry	45	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 189	proteomic profiling by mass spectrometry	45	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 189	proteomic profiling by mass spectrometry	45	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 189	proteomic profiling by mass spectrometry	45	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 189	proteomic profiling by mass spectrometry	45	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 189	proteomic profiling by mass spectrometry	45	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 189	proteomic profiling by mass spectrometry	45	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 189	proteomic profiling by mass spectrometry	45	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 189	proteomic profiling by mass spectrometry	45	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 190	proteomic profiling by mass spectrometry	46	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 190	proteomic profiling by mass spectrometry	46	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 190	proteomic profiling by mass spectrometry	46	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 190	proteomic profiling by mass spectrometry	46	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 190	proteomic profiling by mass spectrometry	46	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 190	proteomic profiling by mass spectrometry	46	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 190	proteomic profiling by mass spectrometry	46	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 190	proteomic profiling by mass spectrometry	46	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 190	proteomic profiling by mass spectrometry	46	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 190	proteomic profiling by mass spectrometry	46	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 191	proteomic profiling by mass spectrometry	47	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 191	proteomic profiling by mass spectrometry	47	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 191	proteomic profiling by mass spectrometry	47	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 191	proteomic profiling by mass spectrometry	47	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 191	proteomic profiling by mass spectrometry	47	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 191	proteomic profiling by mass spectrometry	47	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 191	proteomic profiling by mass spectrometry	47	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 191	proteomic profiling by mass spectrometry	47	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 191	proteomic profiling by mass spectrometry	47	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 191	proteomic profiling by mass spectrometry	47	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 192	proteomic profiling by mass spectrometry	48	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 192	proteomic profiling by mass spectrometry	48	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 192	proteomic profiling by mass spectrometry	48	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 192	proteomic profiling by mass spectrometry	48	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 192	proteomic profiling by mass spectrometry	48	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 192	proteomic profiling by mass spectrometry	48	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 192	proteomic profiling by mass spectrometry	48	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 192	proteomic profiling by mass spectrometry	48	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 192	proteomic profiling by mass spectrometry	48	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 192	proteomic profiling by mass spectrometry	48	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 193	proteomic profiling by mass spectrometry	49	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 193	proteomic profiling by mass spectrometry	49	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 193	proteomic profiling by mass spectrometry	49	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 193	proteomic profiling by mass spectrometry	49	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 193	proteomic profiling by mass spectrometry	49	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 193	proteomic profiling by mass spectrometry	49	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 193	proteomic profiling by mass spectrometry	49	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 193	proteomic profiling by mass spectrometry	49	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 193	proteomic profiling by mass spectrometry	49	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 193	proteomic profiling by mass spectrometry	49	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 194	proteomic profiling by mass spectrometry	50	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 194	proteomic profiling by mass spectrometry	50	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 194	proteomic profiling by mass spectrometry	50	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 194	proteomic profiling by mass spectrometry	50	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 194	proteomic profiling by mass spectrometry	50	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 194	proteomic profiling by mass spectrometry	50	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 194	proteomic profiling by mass spectrometry	50	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 194	proteomic profiling by mass spectrometry	50	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 194	proteomic profiling by mass spectrometry	50	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 194	proteomic profiling by mass spectrometry	50	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 195	proteomic profiling by mass spectrometry	51	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 195	proteomic profiling by mass spectrometry	51	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 195	proteomic profiling by mass spectrometry	51	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 195	proteomic profiling by mass spectrometry	51	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 195	proteomic profiling by mass spectrometry	51	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 195	proteomic profiling by mass spectrometry	51	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 195	proteomic profiling by mass spectrometry	51	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 195	proteomic profiling by mass spectrometry	51	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 195	proteomic profiling by mass spectrometry	51	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 195	proteomic profiling by mass spectrometry	51	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 196	proteomic profiling by mass spectrometry	52	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 196	proteomic profiling by mass spectrometry	52	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 196	proteomic profiling by mass spectrometry	52	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 196	proteomic profiling by mass spectrometry	52	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 196	proteomic profiling by mass spectrometry	52	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 196	proteomic profiling by mass spectrometry	52	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 196	proteomic profiling by mass spectrometry	52	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 196	proteomic profiling by mass spectrometry	52	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 196	proteomic profiling by mass spectrometry	52	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 196	proteomic profiling by mass spectrometry	52	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 197	proteomic profiling by mass spectrometry	53	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 197	proteomic profiling by mass spectrometry	53	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 197	proteomic profiling by mass spectrometry	53	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 197	proteomic profiling by mass spectrometry	53	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 197	proteomic profiling by mass spectrometry	53	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 197	proteomic profiling by mass spectrometry	53	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 197	proteomic profiling by mass spectrometry	53	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 197	proteomic profiling by mass spectrometry	53	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 197	proteomic profiling by mass spectrometry	53	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 197	proteomic profiling by mass spectrometry	53	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 198	proteomic profiling by mass spectrometry	54	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 198	proteomic profiling by mass spectrometry	54	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 198	proteomic profiling by mass spectrometry	54	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 198	proteomic profiling by mass spectrometry	54	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 198	proteomic profiling by mass spectrometry	54	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 198	proteomic profiling by mass spectrometry	54	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 198	proteomic profiling by mass spectrometry	54	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 198	proteomic profiling by mass spectrometry	54	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 198	proteomic profiling by mass spectrometry	54	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 198	proteomic profiling by mass spectrometry	54	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 199	proteomic profiling by mass spectrometry	55	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 199	proteomic profiling by mass spectrometry	55	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 199	proteomic profiling by mass spectrometry	55	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 199	proteomic profiling by mass spectrometry	55	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 199	proteomic profiling by mass spectrometry	55	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 199	proteomic profiling by mass spectrometry	55	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 199	proteomic profiling by mass spectrometry	55	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 199	proteomic profiling by mass spectrometry	55	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 199	proteomic profiling by mass spectrometry	55	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 199	proteomic profiling by mass spectrometry	55	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 200	proteomic profiling by mass spectrometry	56	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 200	proteomic profiling by mass spectrometry	56	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 200	proteomic profiling by mass spectrometry	56	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 200	proteomic profiling by mass spectrometry	56	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 200	proteomic profiling by mass spectrometry	56	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 200	proteomic profiling by mass spectrometry	56	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 200	proteomic profiling by mass spectrometry	56	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 200	proteomic profiling by mass spectrometry	56	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 200	proteomic profiling by mass spectrometry	56	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 200	proteomic profiling by mass spectrometry	56	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 201	proteomic profiling by mass spectrometry	57	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 201	proteomic profiling by mass spectrometry	57	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 201	proteomic profiling by mass spectrometry	57	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 201	proteomic profiling by mass spectrometry	57	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 201	proteomic profiling by mass spectrometry	57	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 201	proteomic profiling by mass spectrometry	57	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 201	proteomic profiling by mass spectrometry	57	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 201	proteomic profiling by mass spectrometry	57	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 201	proteomic profiling by mass spectrometry	57	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 201	proteomic profiling by mass spectrometry	57	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 202	proteomic profiling by mass spectrometry	58	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 202	proteomic profiling by mass spectrometry	58	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 202	proteomic profiling by mass spectrometry	58	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 202	proteomic profiling by mass spectrometry	58	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 202	proteomic profiling by mass spectrometry	58	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 202	proteomic profiling by mass spectrometry	58	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 202	proteomic profiling by mass spectrometry	58	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 202	proteomic profiling by mass spectrometry	58	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 202	proteomic profiling by mass spectrometry	58	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 202	proteomic profiling by mass spectrometry	58	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 203	proteomic profiling by mass spectrometry	59	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 203	proteomic profiling by mass spectrometry	59	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 203	proteomic profiling by mass spectrometry	59	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 203	proteomic profiling by mass spectrometry	59	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 203	proteomic profiling by mass spectrometry	59	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 203	proteomic profiling by mass spectrometry	59	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 203	proteomic profiling by mass spectrometry	59	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 203	proteomic profiling by mass spectrometry	59	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 203	proteomic profiling by mass spectrometry	59	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 203	proteomic profiling by mass spectrometry	59	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 204	proteomic profiling by mass spectrometry	60	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 204	proteomic profiling by mass spectrometry	60	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 204	proteomic profiling by mass spectrometry	60	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 204	proteomic profiling by mass spectrometry	60	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 204	proteomic profiling by mass spectrometry	60	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 204	proteomic profiling by mass spectrometry	60	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 204	proteomic profiling by mass spectrometry	60	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 204	proteomic profiling by mass spectrometry	60	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 204	proteomic profiling by mass spectrometry	60	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 204	proteomic profiling by mass spectrometry	60	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 205	proteomic profiling by mass spectrometry	61	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 205	proteomic profiling by mass spectrometry	61	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 205	proteomic profiling by mass spectrometry	61	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 205	proteomic profiling by mass spectrometry	61	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 205	proteomic profiling by mass spectrometry	61	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 205	proteomic profiling by mass spectrometry	61	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 205	proteomic profiling by mass spectrometry	61	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 205	proteomic profiling by mass spectrometry	61	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 205	proteomic profiling by mass spectrometry	61	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 205	proteomic profiling by mass spectrometry	61	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 206	proteomic profiling by mass spectrometry	62	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 206	proteomic profiling by mass spectrometry	62	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 206	proteomic profiling by mass spectrometry	62	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 206	proteomic profiling by mass spectrometry	62	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 206	proteomic profiling by mass spectrometry	62	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 206	proteomic profiling by mass spectrometry	62	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 206	proteomic profiling by mass spectrometry	62	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 206	proteomic profiling by mass spectrometry	62	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 206	proteomic profiling by mass spectrometry	62	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 206	proteomic profiling by mass spectrometry	62	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 207	proteomic profiling by mass spectrometry	63	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 207	proteomic profiling by mass spectrometry	63	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 207	proteomic profiling by mass spectrometry	63	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 207	proteomic profiling by mass spectrometry	63	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 207	proteomic profiling by mass spectrometry	63	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 207	proteomic profiling by mass spectrometry	63	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 207	proteomic profiling by mass spectrometry	63	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 207	proteomic profiling by mass spectrometry	63	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 207	proteomic profiling by mass spectrometry	63	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 207	proteomic profiling by mass spectrometry	63	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 208	proteomic profiling by mass spectrometry	64	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 208	proteomic profiling by mass spectrometry	64	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 208	proteomic profiling by mass spectrometry	64	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 208	proteomic profiling by mass spectrometry	64	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 208	proteomic profiling by mass spectrometry	64	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 208	proteomic profiling by mass spectrometry	64	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 208	proteomic profiling by mass spectrometry	64	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 208	proteomic profiling by mass spectrometry	64	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 208	proteomic profiling by mass spectrometry	64	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 208	proteomic profiling by mass spectrometry	64	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 209	proteomic profiling by mass spectrometry	65	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 209	proteomic profiling by mass spectrometry	65	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 209	proteomic profiling by mass spectrometry	65	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 209	proteomic profiling by mass spectrometry	65	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 209	proteomic profiling by mass spectrometry	65	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 209	proteomic profiling by mass spectrometry	65	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 209	proteomic profiling by mass spectrometry	65	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 209	proteomic profiling by mass spectrometry	65	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 209	proteomic profiling by mass spectrometry	65	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 209	proteomic profiling by mass spectrometry	65	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 210	proteomic profiling by mass spectrometry	66	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 210	proteomic profiling by mass spectrometry	66	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 210	proteomic profiling by mass spectrometry	66	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 210	proteomic profiling by mass spectrometry	66	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 210	proteomic profiling by mass spectrometry	66	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 210	proteomic profiling by mass spectrometry	66	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 210	proteomic profiling by mass spectrometry	66	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 210	proteomic profiling by mass spectrometry	66	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 210	proteomic profiling by mass spectrometry	66	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 210	proteomic profiling by mass spectrometry	66	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 211	proteomic profiling by mass spectrometry	67	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 211	proteomic profiling by mass spectrometry	67	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 211	proteomic profiling by mass spectrometry	67	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 211	proteomic profiling by mass spectrometry	67	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 211	proteomic profiling by mass spectrometry	67	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 211	proteomic profiling by mass spectrometry	67	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 211	proteomic profiling by mass spectrometry	67	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 211	proteomic profiling by mass spectrometry	67	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 211	proteomic profiling by mass spectrometry	67	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 211	proteomic profiling by mass spectrometry	67	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 212	proteomic profiling by mass spectrometry	68	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 212	proteomic profiling by mass spectrometry	68	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 212	proteomic profiling by mass spectrometry	68	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 212	proteomic profiling by mass spectrometry	68	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 212	proteomic profiling by mass spectrometry	68	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 212	proteomic profiling by mass spectrometry	68	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 212	proteomic profiling by mass spectrometry	68	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 212	proteomic profiling by mass spectrometry	68	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 212	proteomic profiling by mass spectrometry	68	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 212	proteomic profiling by mass spectrometry	68	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 213	proteomic profiling by mass spectrometry	69	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 213	proteomic profiling by mass spectrometry	69	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 213	proteomic profiling by mass spectrometry	69	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 213	proteomic profiling by mass spectrometry	69	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 213	proteomic profiling by mass spectrometry	69	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 213	proteomic profiling by mass spectrometry	69	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 213	proteomic profiling by mass spectrometry	69	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 213	proteomic profiling by mass spectrometry	69	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 213	proteomic profiling by mass spectrometry	69	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 213	proteomic profiling by mass spectrometry	69	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 214	proteomic profiling by mass spectrometry	70	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 214	proteomic profiling by mass spectrometry	70	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 214	proteomic profiling by mass spectrometry	70	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 214	proteomic profiling by mass spectrometry	70	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 214	proteomic profiling by mass spectrometry	70	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 214	proteomic profiling by mass spectrometry	70	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 214	proteomic profiling by mass spectrometry	70	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 214	proteomic profiling by mass spectrometry	70	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 214	proteomic profiling by mass spectrometry	70	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 214	proteomic profiling by mass spectrometry	70	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 215	proteomic profiling by mass spectrometry	71	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 215	proteomic profiling by mass spectrometry	71	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 215	proteomic profiling by mass spectrometry	71	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 215	proteomic profiling by mass spectrometry	71	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 215	proteomic profiling by mass spectrometry	71	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 215	proteomic profiling by mass spectrometry	71	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 215	proteomic profiling by mass spectrometry	71	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 215	proteomic profiling by mass spectrometry	71	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 215	proteomic profiling by mass spectrometry	71	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 215	proteomic profiling by mass spectrometry	71	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 21	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_066	tissue	run 216	proteomic profiling by mass spectrometry	72	TMT126	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 22	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_071	tissue	run 216	proteomic profiling by mass spectrometry	72	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 23	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_071	tissue	run 216	proteomic profiling by mass spectrometry	72	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 24	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_072	tissue	run 216	proteomic profiling by mass spectrometry	72	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 25	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_072	tissue	run 216	proteomic profiling by mass spectrometry	72	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 26	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_073	tissue	run 216	proteomic profiling by mass spectrometry	72	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 27	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_073	tissue	run 216	proteomic profiling by mass spectrometry	72	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 28	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_076	tissue	run 216	proteomic profiling by mass spectrometry	72	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 29	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_076	tissue	run 216	proteomic profiling by mass spectrometry	72	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 30	Homo sapiens	blood plasma	3	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS3	tissue	run 216	proteomic profiling by mass spectrometry	72	TMT131	LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set3_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 217	proteomic profiling by mass spectrometry	1	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 217	proteomic profiling by mass spectrometry	1	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 217	proteomic profiling by mass spectrometry	1	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 217	proteomic profiling by mass spectrometry	1	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 217	proteomic profiling by mass spectrometry	1	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 217	proteomic profiling by mass spectrometry	1	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 217	proteomic profiling by mass spectrometry	1	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 217	proteomic profiling by mass spectrometry	1	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 217	proteomic profiling by mass spectrometry	1	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 217	proteomic profiling by mass spectrometry	1	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 218	proteomic profiling by mass spectrometry	2	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 218	proteomic profiling by mass spectrometry	2	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 218	proteomic profiling by mass spectrometry	2	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 218	proteomic profiling by mass spectrometry	2	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 218	proteomic profiling by mass spectrometry	2	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 218	proteomic profiling by mass spectrometry	2	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 218	proteomic profiling by mass spectrometry	2	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 218	proteomic profiling by mass spectrometry	2	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 218	proteomic profiling by mass spectrometry	2	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 218	proteomic profiling by mass spectrometry	2	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 219	proteomic profiling by mass spectrometry	3	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 219	proteomic profiling by mass spectrometry	3	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 219	proteomic profiling by mass spectrometry	3	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 219	proteomic profiling by mass spectrometry	3	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 219	proteomic profiling by mass spectrometry	3	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 219	proteomic profiling by mass spectrometry	3	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 219	proteomic profiling by mass spectrometry	3	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 219	proteomic profiling by mass spectrometry	3	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 219	proteomic profiling by mass spectrometry	3	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 219	proteomic profiling by mass spectrometry	3	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 220	proteomic profiling by mass spectrometry	4	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 220	proteomic profiling by mass spectrometry	4	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 220	proteomic profiling by mass spectrometry	4	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 220	proteomic profiling by mass spectrometry	4	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 220	proteomic profiling by mass spectrometry	4	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 220	proteomic profiling by mass spectrometry	4	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 220	proteomic profiling by mass spectrometry	4	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 220	proteomic profiling by mass spectrometry	4	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 220	proteomic profiling by mass spectrometry	4	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 220	proteomic profiling by mass spectrometry	4	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 221	proteomic profiling by mass spectrometry	5	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 221	proteomic profiling by mass spectrometry	5	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 221	proteomic profiling by mass spectrometry	5	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 221	proteomic profiling by mass spectrometry	5	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 221	proteomic profiling by mass spectrometry	5	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 221	proteomic profiling by mass spectrometry	5	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 221	proteomic profiling by mass spectrometry	5	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 221	proteomic profiling by mass spectrometry	5	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 221	proteomic profiling by mass spectrometry	5	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 221	proteomic profiling by mass spectrometry	5	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 222	proteomic profiling by mass spectrometry	6	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 222	proteomic profiling by mass spectrometry	6	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 222	proteomic profiling by mass spectrometry	6	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 222	proteomic profiling by mass spectrometry	6	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 222	proteomic profiling by mass spectrometry	6	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 222	proteomic profiling by mass spectrometry	6	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 222	proteomic profiling by mass spectrometry	6	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 222	proteomic profiling by mass spectrometry	6	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 222	proteomic profiling by mass spectrometry	6	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 222	proteomic profiling by mass spectrometry	6	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 223	proteomic profiling by mass spectrometry	7	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 223	proteomic profiling by mass spectrometry	7	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 223	proteomic profiling by mass spectrometry	7	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 223	proteomic profiling by mass spectrometry	7	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 223	proteomic profiling by mass spectrometry	7	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 223	proteomic profiling by mass spectrometry	7	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 223	proteomic profiling by mass spectrometry	7	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 223	proteomic profiling by mass spectrometry	7	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 223	proteomic profiling by mass spectrometry	7	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 223	proteomic profiling by mass spectrometry	7	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 224	proteomic profiling by mass spectrometry	8	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 224	proteomic profiling by mass spectrometry	8	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 224	proteomic profiling by mass spectrometry	8	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 224	proteomic profiling by mass spectrometry	8	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 224	proteomic profiling by mass spectrometry	8	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 224	proteomic profiling by mass spectrometry	8	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 224	proteomic profiling by mass spectrometry	8	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 224	proteomic profiling by mass spectrometry	8	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 224	proteomic profiling by mass spectrometry	8	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 224	proteomic profiling by mass spectrometry	8	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 225	proteomic profiling by mass spectrometry	9	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 225	proteomic profiling by mass spectrometry	9	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 225	proteomic profiling by mass spectrometry	9	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 225	proteomic profiling by mass spectrometry	9	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 225	proteomic profiling by mass spectrometry	9	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 225	proteomic profiling by mass spectrometry	9	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 225	proteomic profiling by mass spectrometry	9	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 225	proteomic profiling by mass spectrometry	9	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 225	proteomic profiling by mass spectrometry	9	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 225	proteomic profiling by mass spectrometry	9	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 226	proteomic profiling by mass spectrometry	10	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 226	proteomic profiling by mass spectrometry	10	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 226	proteomic profiling by mass spectrometry	10	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 226	proteomic profiling by mass spectrometry	10	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 226	proteomic profiling by mass spectrometry	10	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 226	proteomic profiling by mass spectrometry	10	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 226	proteomic profiling by mass spectrometry	10	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 226	proteomic profiling by mass spectrometry	10	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 226	proteomic profiling by mass spectrometry	10	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 226	proteomic profiling by mass spectrometry	10	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 227	proteomic profiling by mass spectrometry	11	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 227	proteomic profiling by mass spectrometry	11	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 227	proteomic profiling by mass spectrometry	11	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 227	proteomic profiling by mass spectrometry	11	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 227	proteomic profiling by mass spectrometry	11	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 227	proteomic profiling by mass spectrometry	11	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 227	proteomic profiling by mass spectrometry	11	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 227	proteomic profiling by mass spectrometry	11	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 227	proteomic profiling by mass spectrometry	11	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 227	proteomic profiling by mass spectrometry	11	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 228	proteomic profiling by mass spectrometry	12	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 228	proteomic profiling by mass spectrometry	12	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 228	proteomic profiling by mass spectrometry	12	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 228	proteomic profiling by mass spectrometry	12	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 228	proteomic profiling by mass spectrometry	12	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 228	proteomic profiling by mass spectrometry	12	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 228	proteomic profiling by mass spectrometry	12	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 228	proteomic profiling by mass spectrometry	12	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 228	proteomic profiling by mass spectrometry	12	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 228	proteomic profiling by mass spectrometry	12	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 229	proteomic profiling by mass spectrometry	13	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 229	proteomic profiling by mass spectrometry	13	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 229	proteomic profiling by mass spectrometry	13	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 229	proteomic profiling by mass spectrometry	13	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 229	proteomic profiling by mass spectrometry	13	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 229	proteomic profiling by mass spectrometry	13	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 229	proteomic profiling by mass spectrometry	13	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 229	proteomic profiling by mass spectrometry	13	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 229	proteomic profiling by mass spectrometry	13	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 229	proteomic profiling by mass spectrometry	13	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 230	proteomic profiling by mass spectrometry	14	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 230	proteomic profiling by mass spectrometry	14	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 230	proteomic profiling by mass spectrometry	14	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 230	proteomic profiling by mass spectrometry	14	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 230	proteomic profiling by mass spectrometry	14	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 230	proteomic profiling by mass spectrometry	14	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 230	proteomic profiling by mass spectrometry	14	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 230	proteomic profiling by mass spectrometry	14	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 230	proteomic profiling by mass spectrometry	14	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 230	proteomic profiling by mass spectrometry	14	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 231	proteomic profiling by mass spectrometry	15	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 231	proteomic profiling by mass spectrometry	15	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 231	proteomic profiling by mass spectrometry	15	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 231	proteomic profiling by mass spectrometry	15	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 231	proteomic profiling by mass spectrometry	15	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 231	proteomic profiling by mass spectrometry	15	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 231	proteomic profiling by mass spectrometry	15	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 231	proteomic profiling by mass spectrometry	15	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 231	proteomic profiling by mass spectrometry	15	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 231	proteomic profiling by mass spectrometry	15	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 232	proteomic profiling by mass spectrometry	16	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 232	proteomic profiling by mass spectrometry	16	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 232	proteomic profiling by mass spectrometry	16	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 232	proteomic profiling by mass spectrometry	16	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 232	proteomic profiling by mass spectrometry	16	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 232	proteomic profiling by mass spectrometry	16	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 232	proteomic profiling by mass spectrometry	16	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 232	proteomic profiling by mass spectrometry	16	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 232	proteomic profiling by mass spectrometry	16	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 232	proteomic profiling by mass spectrometry	16	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 233	proteomic profiling by mass spectrometry	17	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 233	proteomic profiling by mass spectrometry	17	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 233	proteomic profiling by mass spectrometry	17	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 233	proteomic profiling by mass spectrometry	17	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 233	proteomic profiling by mass spectrometry	17	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 233	proteomic profiling by mass spectrometry	17	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 233	proteomic profiling by mass spectrometry	17	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 233	proteomic profiling by mass spectrometry	17	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 233	proteomic profiling by mass spectrometry	17	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 233	proteomic profiling by mass spectrometry	17	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 234	proteomic profiling by mass spectrometry	18	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 234	proteomic profiling by mass spectrometry	18	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 234	proteomic profiling by mass spectrometry	18	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 234	proteomic profiling by mass spectrometry	18	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 234	proteomic profiling by mass spectrometry	18	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 234	proteomic profiling by mass spectrometry	18	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 234	proteomic profiling by mass spectrometry	18	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 234	proteomic profiling by mass spectrometry	18	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 234	proteomic profiling by mass spectrometry	18	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 234	proteomic profiling by mass spectrometry	18	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 235	proteomic profiling by mass spectrometry	19	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 235	proteomic profiling by mass spectrometry	19	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 235	proteomic profiling by mass spectrometry	19	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 235	proteomic profiling by mass spectrometry	19	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 235	proteomic profiling by mass spectrometry	19	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 235	proteomic profiling by mass spectrometry	19	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 235	proteomic profiling by mass spectrometry	19	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 235	proteomic profiling by mass spectrometry	19	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 235	proteomic profiling by mass spectrometry	19	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 235	proteomic profiling by mass spectrometry	19	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 236	proteomic profiling by mass spectrometry	20	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 236	proteomic profiling by mass spectrometry	20	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 236	proteomic profiling by mass spectrometry	20	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 236	proteomic profiling by mass spectrometry	20	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 236	proteomic profiling by mass spectrometry	20	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 236	proteomic profiling by mass spectrometry	20	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 236	proteomic profiling by mass spectrometry	20	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 236	proteomic profiling by mass spectrometry	20	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 236	proteomic profiling by mass spectrometry	20	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 236	proteomic profiling by mass spectrometry	20	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 237	proteomic profiling by mass spectrometry	21	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 237	proteomic profiling by mass spectrometry	21	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 237	proteomic profiling by mass spectrometry	21	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 237	proteomic profiling by mass spectrometry	21	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 237	proteomic profiling by mass spectrometry	21	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 237	proteomic profiling by mass spectrometry	21	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 237	proteomic profiling by mass spectrometry	21	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 237	proteomic profiling by mass spectrometry	21	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 237	proteomic profiling by mass spectrometry	21	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 237	proteomic profiling by mass spectrometry	21	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 238	proteomic profiling by mass spectrometry	22	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 238	proteomic profiling by mass spectrometry	22	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 238	proteomic profiling by mass spectrometry	22	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 238	proteomic profiling by mass spectrometry	22	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 238	proteomic profiling by mass spectrometry	22	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 238	proteomic profiling by mass spectrometry	22	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 238	proteomic profiling by mass spectrometry	22	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 238	proteomic profiling by mass spectrometry	22	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 238	proteomic profiling by mass spectrometry	22	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 238	proteomic profiling by mass spectrometry	22	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 239	proteomic profiling by mass spectrometry	23	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 239	proteomic profiling by mass spectrometry	23	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 239	proteomic profiling by mass spectrometry	23	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 239	proteomic profiling by mass spectrometry	23	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 239	proteomic profiling by mass spectrometry	23	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 239	proteomic profiling by mass spectrometry	23	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 239	proteomic profiling by mass spectrometry	23	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 239	proteomic profiling by mass spectrometry	23	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 239	proteomic profiling by mass spectrometry	23	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 239	proteomic profiling by mass spectrometry	23	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 240	proteomic profiling by mass spectrometry	24	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 240	proteomic profiling by mass spectrometry	24	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 240	proteomic profiling by mass spectrometry	24	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 240	proteomic profiling by mass spectrometry	24	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 240	proteomic profiling by mass spectrometry	24	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 240	proteomic profiling by mass spectrometry	24	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 240	proteomic profiling by mass spectrometry	24	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 240	proteomic profiling by mass spectrometry	24	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 240	proteomic profiling by mass spectrometry	24	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 240	proteomic profiling by mass spectrometry	24	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 241	proteomic profiling by mass spectrometry	25	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 241	proteomic profiling by mass spectrometry	25	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 241	proteomic profiling by mass spectrometry	25	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 241	proteomic profiling by mass spectrometry	25	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 241	proteomic profiling by mass spectrometry	25	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 241	proteomic profiling by mass spectrometry	25	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 241	proteomic profiling by mass spectrometry	25	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 241	proteomic profiling by mass spectrometry	25	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 241	proteomic profiling by mass spectrometry	25	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 241	proteomic profiling by mass spectrometry	25	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 242	proteomic profiling by mass spectrometry	26	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 242	proteomic profiling by mass spectrometry	26	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 242	proteomic profiling by mass spectrometry	26	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 242	proteomic profiling by mass spectrometry	26	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 242	proteomic profiling by mass spectrometry	26	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 242	proteomic profiling by mass spectrometry	26	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 242	proteomic profiling by mass spectrometry	26	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 242	proteomic profiling by mass spectrometry	26	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 242	proteomic profiling by mass spectrometry	26	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 242	proteomic profiling by mass spectrometry	26	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 243	proteomic profiling by mass spectrometry	27	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 243	proteomic profiling by mass spectrometry	27	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 243	proteomic profiling by mass spectrometry	27	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 243	proteomic profiling by mass spectrometry	27	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 243	proteomic profiling by mass spectrometry	27	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 243	proteomic profiling by mass spectrometry	27	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 243	proteomic profiling by mass spectrometry	27	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 243	proteomic profiling by mass spectrometry	27	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 243	proteomic profiling by mass spectrometry	27	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 243	proteomic profiling by mass spectrometry	27	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 244	proteomic profiling by mass spectrometry	28	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 244	proteomic profiling by mass spectrometry	28	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 244	proteomic profiling by mass spectrometry	28	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 244	proteomic profiling by mass spectrometry	28	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 244	proteomic profiling by mass spectrometry	28	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 244	proteomic profiling by mass spectrometry	28	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 244	proteomic profiling by mass spectrometry	28	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 244	proteomic profiling by mass spectrometry	28	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 244	proteomic profiling by mass spectrometry	28	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 244	proteomic profiling by mass spectrometry	28	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 245	proteomic profiling by mass spectrometry	29	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 245	proteomic profiling by mass spectrometry	29	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 245	proteomic profiling by mass spectrometry	29	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 245	proteomic profiling by mass spectrometry	29	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 245	proteomic profiling by mass spectrometry	29	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 245	proteomic profiling by mass spectrometry	29	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 245	proteomic profiling by mass spectrometry	29	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 245	proteomic profiling by mass spectrometry	29	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 245	proteomic profiling by mass spectrometry	29	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 245	proteomic profiling by mass spectrometry	29	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 246	proteomic profiling by mass spectrometry	30	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 246	proteomic profiling by mass spectrometry	30	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 246	proteomic profiling by mass spectrometry	30	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 246	proteomic profiling by mass spectrometry	30	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 246	proteomic profiling by mass spectrometry	30	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 246	proteomic profiling by mass spectrometry	30	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 246	proteomic profiling by mass spectrometry	30	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 246	proteomic profiling by mass spectrometry	30	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 246	proteomic profiling by mass spectrometry	30	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 246	proteomic profiling by mass spectrometry	30	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 247	proteomic profiling by mass spectrometry	31	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 247	proteomic profiling by mass spectrometry	31	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 247	proteomic profiling by mass spectrometry	31	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 247	proteomic profiling by mass spectrometry	31	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 247	proteomic profiling by mass spectrometry	31	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 247	proteomic profiling by mass spectrometry	31	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 247	proteomic profiling by mass spectrometry	31	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 247	proteomic profiling by mass spectrometry	31	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 247	proteomic profiling by mass spectrometry	31	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 247	proteomic profiling by mass spectrometry	31	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 248	proteomic profiling by mass spectrometry	32	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 248	proteomic profiling by mass spectrometry	32	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 248	proteomic profiling by mass spectrometry	32	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 248	proteomic profiling by mass spectrometry	32	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 248	proteomic profiling by mass spectrometry	32	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 248	proteomic profiling by mass spectrometry	32	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 248	proteomic profiling by mass spectrometry	32	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 248	proteomic profiling by mass spectrometry	32	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 248	proteomic profiling by mass spectrometry	32	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 248	proteomic profiling by mass spectrometry	32	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 249	proteomic profiling by mass spectrometry	33	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 249	proteomic profiling by mass spectrometry	33	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 249	proteomic profiling by mass spectrometry	33	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 249	proteomic profiling by mass spectrometry	33	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 249	proteomic profiling by mass spectrometry	33	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 249	proteomic profiling by mass spectrometry	33	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 249	proteomic profiling by mass spectrometry	33	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 249	proteomic profiling by mass spectrometry	33	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 249	proteomic profiling by mass spectrometry	33	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 249	proteomic profiling by mass spectrometry	33	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 250	proteomic profiling by mass spectrometry	34	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 250	proteomic profiling by mass spectrometry	34	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 250	proteomic profiling by mass spectrometry	34	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 250	proteomic profiling by mass spectrometry	34	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 250	proteomic profiling by mass spectrometry	34	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 250	proteomic profiling by mass spectrometry	34	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 250	proteomic profiling by mass spectrometry	34	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 250	proteomic profiling by mass spectrometry	34	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 250	proteomic profiling by mass spectrometry	34	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 250	proteomic profiling by mass spectrometry	34	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 251	proteomic profiling by mass spectrometry	35	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 251	proteomic profiling by mass spectrometry	35	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 251	proteomic profiling by mass spectrometry	35	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 251	proteomic profiling by mass spectrometry	35	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 251	proteomic profiling by mass spectrometry	35	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 251	proteomic profiling by mass spectrometry	35	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 251	proteomic profiling by mass spectrometry	35	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 251	proteomic profiling by mass spectrometry	35	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 251	proteomic profiling by mass spectrometry	35	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 251	proteomic profiling by mass spectrometry	35	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 252	proteomic profiling by mass spectrometry	36	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 252	proteomic profiling by mass spectrometry	36	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 252	proteomic profiling by mass spectrometry	36	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 252	proteomic profiling by mass spectrometry	36	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 252	proteomic profiling by mass spectrometry	36	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 252	proteomic profiling by mass spectrometry	36	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 252	proteomic profiling by mass spectrometry	36	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 252	proteomic profiling by mass spectrometry	36	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 252	proteomic profiling by mass spectrometry	36	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 252	proteomic profiling by mass spectrometry	36	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 253	proteomic profiling by mass spectrometry	37	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 253	proteomic profiling by mass spectrometry	37	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 253	proteomic profiling by mass spectrometry	37	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 253	proteomic profiling by mass spectrometry	37	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 253	proteomic profiling by mass spectrometry	37	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 253	proteomic profiling by mass spectrometry	37	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 253	proteomic profiling by mass spectrometry	37	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 253	proteomic profiling by mass spectrometry	37	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 253	proteomic profiling by mass spectrometry	37	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 253	proteomic profiling by mass spectrometry	37	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 254	proteomic profiling by mass spectrometry	38	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 254	proteomic profiling by mass spectrometry	38	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 254	proteomic profiling by mass spectrometry	38	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 254	proteomic profiling by mass spectrometry	38	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 254	proteomic profiling by mass spectrometry	38	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 254	proteomic profiling by mass spectrometry	38	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 254	proteomic profiling by mass spectrometry	38	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 254	proteomic profiling by mass spectrometry	38	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 254	proteomic profiling by mass spectrometry	38	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 254	proteomic profiling by mass spectrometry	38	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 255	proteomic profiling by mass spectrometry	39	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 255	proteomic profiling by mass spectrometry	39	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 255	proteomic profiling by mass spectrometry	39	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 255	proteomic profiling by mass spectrometry	39	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 255	proteomic profiling by mass spectrometry	39	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 255	proteomic profiling by mass spectrometry	39	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 255	proteomic profiling by mass spectrometry	39	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 255	proteomic profiling by mass spectrometry	39	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 255	proteomic profiling by mass spectrometry	39	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 255	proteomic profiling by mass spectrometry	39	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 256	proteomic profiling by mass spectrometry	40	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 256	proteomic profiling by mass spectrometry	40	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 256	proteomic profiling by mass spectrometry	40	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 256	proteomic profiling by mass spectrometry	40	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 256	proteomic profiling by mass spectrometry	40	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 256	proteomic profiling by mass spectrometry	40	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 256	proteomic profiling by mass spectrometry	40	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 256	proteomic profiling by mass spectrometry	40	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 256	proteomic profiling by mass spectrometry	40	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 256	proteomic profiling by mass spectrometry	40	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 257	proteomic profiling by mass spectrometry	41	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 257	proteomic profiling by mass spectrometry	41	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 257	proteomic profiling by mass spectrometry	41	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 257	proteomic profiling by mass spectrometry	41	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 257	proteomic profiling by mass spectrometry	41	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 257	proteomic profiling by mass spectrometry	41	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 257	proteomic profiling by mass spectrometry	41	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 257	proteomic profiling by mass spectrometry	41	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 257	proteomic profiling by mass spectrometry	41	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 257	proteomic profiling by mass spectrometry	41	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 258	proteomic profiling by mass spectrometry	42	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 258	proteomic profiling by mass spectrometry	42	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 258	proteomic profiling by mass spectrometry	42	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 258	proteomic profiling by mass spectrometry	42	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 258	proteomic profiling by mass spectrometry	42	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 258	proteomic profiling by mass spectrometry	42	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 258	proteomic profiling by mass spectrometry	42	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 258	proteomic profiling by mass spectrometry	42	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 258	proteomic profiling by mass spectrometry	42	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 258	proteomic profiling by mass spectrometry	42	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 259	proteomic profiling by mass spectrometry	43	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 259	proteomic profiling by mass spectrometry	43	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 259	proteomic profiling by mass spectrometry	43	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 259	proteomic profiling by mass spectrometry	43	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 259	proteomic profiling by mass spectrometry	43	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 259	proteomic profiling by mass spectrometry	43	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 259	proteomic profiling by mass spectrometry	43	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 259	proteomic profiling by mass spectrometry	43	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 259	proteomic profiling by mass spectrometry	43	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 259	proteomic profiling by mass spectrometry	43	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 260	proteomic profiling by mass spectrometry	44	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 260	proteomic profiling by mass spectrometry	44	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 260	proteomic profiling by mass spectrometry	44	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 260	proteomic profiling by mass spectrometry	44	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 260	proteomic profiling by mass spectrometry	44	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 260	proteomic profiling by mass spectrometry	44	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 260	proteomic profiling by mass spectrometry	44	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 260	proteomic profiling by mass spectrometry	44	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 260	proteomic profiling by mass spectrometry	44	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 260	proteomic profiling by mass spectrometry	44	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 261	proteomic profiling by mass spectrometry	45	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 261	proteomic profiling by mass spectrometry	45	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 261	proteomic profiling by mass spectrometry	45	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 261	proteomic profiling by mass spectrometry	45	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 261	proteomic profiling by mass spectrometry	45	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 261	proteomic profiling by mass spectrometry	45	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 261	proteomic profiling by mass spectrometry	45	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 261	proteomic profiling by mass spectrometry	45	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 261	proteomic profiling by mass spectrometry	45	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 261	proteomic profiling by mass spectrometry	45	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 262	proteomic profiling by mass spectrometry	46	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 262	proteomic profiling by mass spectrometry	46	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 262	proteomic profiling by mass spectrometry	46	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 262	proteomic profiling by mass spectrometry	46	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 262	proteomic profiling by mass spectrometry	46	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 262	proteomic profiling by mass spectrometry	46	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 262	proteomic profiling by mass spectrometry	46	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 262	proteomic profiling by mass spectrometry	46	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 262	proteomic profiling by mass spectrometry	46	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 262	proteomic profiling by mass spectrometry	46	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 263	proteomic profiling by mass spectrometry	47	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 263	proteomic profiling by mass spectrometry	47	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 263	proteomic profiling by mass spectrometry	47	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 263	proteomic profiling by mass spectrometry	47	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 263	proteomic profiling by mass spectrometry	47	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 263	proteomic profiling by mass spectrometry	47	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 263	proteomic profiling by mass spectrometry	47	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 263	proteomic profiling by mass spectrometry	47	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 263	proteomic profiling by mass spectrometry	47	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 263	proteomic profiling by mass spectrometry	47	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 264	proteomic profiling by mass spectrometry	48	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 264	proteomic profiling by mass spectrometry	48	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 264	proteomic profiling by mass spectrometry	48	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 264	proteomic profiling by mass spectrometry	48	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 264	proteomic profiling by mass spectrometry	48	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 264	proteomic profiling by mass spectrometry	48	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 264	proteomic profiling by mass spectrometry	48	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 264	proteomic profiling by mass spectrometry	48	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 264	proteomic profiling by mass spectrometry	48	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 264	proteomic profiling by mass spectrometry	48	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 265	proteomic profiling by mass spectrometry	49	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 265	proteomic profiling by mass spectrometry	49	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 265	proteomic profiling by mass spectrometry	49	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 265	proteomic profiling by mass spectrometry	49	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 265	proteomic profiling by mass spectrometry	49	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 265	proteomic profiling by mass spectrometry	49	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 265	proteomic profiling by mass spectrometry	49	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 265	proteomic profiling by mass spectrometry	49	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 265	proteomic profiling by mass spectrometry	49	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 265	proteomic profiling by mass spectrometry	49	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 266	proteomic profiling by mass spectrometry	50	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 266	proteomic profiling by mass spectrometry	50	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 266	proteomic profiling by mass spectrometry	50	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 266	proteomic profiling by mass spectrometry	50	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 266	proteomic profiling by mass spectrometry	50	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 266	proteomic profiling by mass spectrometry	50	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 266	proteomic profiling by mass spectrometry	50	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 266	proteomic profiling by mass spectrometry	50	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 266	proteomic profiling by mass spectrometry	50	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 266	proteomic profiling by mass spectrometry	50	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 267	proteomic profiling by mass spectrometry	51	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 267	proteomic profiling by mass spectrometry	51	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 267	proteomic profiling by mass spectrometry	51	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 267	proteomic profiling by mass spectrometry	51	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 267	proteomic profiling by mass spectrometry	51	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 267	proteomic profiling by mass spectrometry	51	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 267	proteomic profiling by mass spectrometry	51	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 267	proteomic profiling by mass spectrometry	51	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 267	proteomic profiling by mass spectrometry	51	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 267	proteomic profiling by mass spectrometry	51	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 268	proteomic profiling by mass spectrometry	52	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 268	proteomic profiling by mass spectrometry	52	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 268	proteomic profiling by mass spectrometry	52	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 268	proteomic profiling by mass spectrometry	52	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 268	proteomic profiling by mass spectrometry	52	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 268	proteomic profiling by mass spectrometry	52	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 268	proteomic profiling by mass spectrometry	52	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 268	proteomic profiling by mass spectrometry	52	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 268	proteomic profiling by mass spectrometry	52	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 268	proteomic profiling by mass spectrometry	52	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 269	proteomic profiling by mass spectrometry	53	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 269	proteomic profiling by mass spectrometry	53	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 269	proteomic profiling by mass spectrometry	53	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 269	proteomic profiling by mass spectrometry	53	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 269	proteomic profiling by mass spectrometry	53	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 269	proteomic profiling by mass spectrometry	53	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 269	proteomic profiling by mass spectrometry	53	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 269	proteomic profiling by mass spectrometry	53	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 269	proteomic profiling by mass spectrometry	53	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 269	proteomic profiling by mass spectrometry	53	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 270	proteomic profiling by mass spectrometry	54	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 270	proteomic profiling by mass spectrometry	54	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 270	proteomic profiling by mass spectrometry	54	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 270	proteomic profiling by mass spectrometry	54	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 270	proteomic profiling by mass spectrometry	54	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 270	proteomic profiling by mass spectrometry	54	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 270	proteomic profiling by mass spectrometry	54	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 270	proteomic profiling by mass spectrometry	54	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 270	proteomic profiling by mass spectrometry	54	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 270	proteomic profiling by mass spectrometry	54	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 271	proteomic profiling by mass spectrometry	55	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 271	proteomic profiling by mass spectrometry	55	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 271	proteomic profiling by mass spectrometry	55	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 271	proteomic profiling by mass spectrometry	55	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 271	proteomic profiling by mass spectrometry	55	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 271	proteomic profiling by mass spectrometry	55	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 271	proteomic profiling by mass spectrometry	55	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 271	proteomic profiling by mass spectrometry	55	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 271	proteomic profiling by mass spectrometry	55	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 271	proteomic profiling by mass spectrometry	55	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 272	proteomic profiling by mass spectrometry	56	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 272	proteomic profiling by mass spectrometry	56	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 272	proteomic profiling by mass spectrometry	56	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 272	proteomic profiling by mass spectrometry	56	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 272	proteomic profiling by mass spectrometry	56	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 272	proteomic profiling by mass spectrometry	56	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 272	proteomic profiling by mass spectrometry	56	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 272	proteomic profiling by mass spectrometry	56	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 272	proteomic profiling by mass spectrometry	56	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 272	proteomic profiling by mass spectrometry	56	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 273	proteomic profiling by mass spectrometry	57	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 273	proteomic profiling by mass spectrometry	57	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 273	proteomic profiling by mass spectrometry	57	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 273	proteomic profiling by mass spectrometry	57	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 273	proteomic profiling by mass spectrometry	57	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 273	proteomic profiling by mass spectrometry	57	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 273	proteomic profiling by mass spectrometry	57	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 273	proteomic profiling by mass spectrometry	57	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 273	proteomic profiling by mass spectrometry	57	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 273	proteomic profiling by mass spectrometry	57	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 274	proteomic profiling by mass spectrometry	58	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 274	proteomic profiling by mass spectrometry	58	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 274	proteomic profiling by mass spectrometry	58	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 274	proteomic profiling by mass spectrometry	58	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 274	proteomic profiling by mass spectrometry	58	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 274	proteomic profiling by mass spectrometry	58	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 274	proteomic profiling by mass spectrometry	58	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 274	proteomic profiling by mass spectrometry	58	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 274	proteomic profiling by mass spectrometry	58	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 274	proteomic profiling by mass spectrometry	58	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 275	proteomic profiling by mass spectrometry	59	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 275	proteomic profiling by mass spectrometry	59	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 275	proteomic profiling by mass spectrometry	59	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 275	proteomic profiling by mass spectrometry	59	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 275	proteomic profiling by mass spectrometry	59	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 275	proteomic profiling by mass spectrometry	59	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 275	proteomic profiling by mass spectrometry	59	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 275	proteomic profiling by mass spectrometry	59	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 275	proteomic profiling by mass spectrometry	59	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 275	proteomic profiling by mass spectrometry	59	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 276	proteomic profiling by mass spectrometry	60	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 276	proteomic profiling by mass spectrometry	60	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 276	proteomic profiling by mass spectrometry	60	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 276	proteomic profiling by mass spectrometry	60	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 276	proteomic profiling by mass spectrometry	60	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 276	proteomic profiling by mass spectrometry	60	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 276	proteomic profiling by mass spectrometry	60	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 276	proteomic profiling by mass spectrometry	60	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 276	proteomic profiling by mass spectrometry	60	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 276	proteomic profiling by mass spectrometry	60	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 277	proteomic profiling by mass spectrometry	61	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 277	proteomic profiling by mass spectrometry	61	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 277	proteomic profiling by mass spectrometry	61	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 277	proteomic profiling by mass spectrometry	61	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 277	proteomic profiling by mass spectrometry	61	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 277	proteomic profiling by mass spectrometry	61	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 277	proteomic profiling by mass spectrometry	61	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 277	proteomic profiling by mass spectrometry	61	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 277	proteomic profiling by mass spectrometry	61	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 277	proteomic profiling by mass spectrometry	61	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 278	proteomic profiling by mass spectrometry	62	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 278	proteomic profiling by mass spectrometry	62	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 278	proteomic profiling by mass spectrometry	62	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 278	proteomic profiling by mass spectrometry	62	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 278	proteomic profiling by mass spectrometry	62	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 278	proteomic profiling by mass spectrometry	62	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 278	proteomic profiling by mass spectrometry	62	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 278	proteomic profiling by mass spectrometry	62	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 278	proteomic profiling by mass spectrometry	62	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 278	proteomic profiling by mass spectrometry	62	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 279	proteomic profiling by mass spectrometry	63	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 279	proteomic profiling by mass spectrometry	63	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 279	proteomic profiling by mass spectrometry	63	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 279	proteomic profiling by mass spectrometry	63	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 279	proteomic profiling by mass spectrometry	63	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 279	proteomic profiling by mass spectrometry	63	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 279	proteomic profiling by mass spectrometry	63	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 279	proteomic profiling by mass spectrometry	63	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 279	proteomic profiling by mass spectrometry	63	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 279	proteomic profiling by mass spectrometry	63	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 280	proteomic profiling by mass spectrometry	64	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 280	proteomic profiling by mass spectrometry	64	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 280	proteomic profiling by mass spectrometry	64	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 280	proteomic profiling by mass spectrometry	64	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 280	proteomic profiling by mass spectrometry	64	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 280	proteomic profiling by mass spectrometry	64	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 280	proteomic profiling by mass spectrometry	64	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 280	proteomic profiling by mass spectrometry	64	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 280	proteomic profiling by mass spectrometry	64	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 280	proteomic profiling by mass spectrometry	64	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 281	proteomic profiling by mass spectrometry	65	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 281	proteomic profiling by mass spectrometry	65	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 281	proteomic profiling by mass spectrometry	65	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 281	proteomic profiling by mass spectrometry	65	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 281	proteomic profiling by mass spectrometry	65	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 281	proteomic profiling by mass spectrometry	65	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 281	proteomic profiling by mass spectrometry	65	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 281	proteomic profiling by mass spectrometry	65	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 281	proteomic profiling by mass spectrometry	65	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 281	proteomic profiling by mass spectrometry	65	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 282	proteomic profiling by mass spectrometry	66	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 282	proteomic profiling by mass spectrometry	66	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 282	proteomic profiling by mass spectrometry	66	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 282	proteomic profiling by mass spectrometry	66	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 282	proteomic profiling by mass spectrometry	66	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 282	proteomic profiling by mass spectrometry	66	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 282	proteomic profiling by mass spectrometry	66	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 282	proteomic profiling by mass spectrometry	66	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 282	proteomic profiling by mass spectrometry	66	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 282	proteomic profiling by mass spectrometry	66	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 283	proteomic profiling by mass spectrometry	67	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 283	proteomic profiling by mass spectrometry	67	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 283	proteomic profiling by mass spectrometry	67	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 283	proteomic profiling by mass spectrometry	67	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 283	proteomic profiling by mass spectrometry	67	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 283	proteomic profiling by mass spectrometry	67	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 283	proteomic profiling by mass spectrometry	67	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 283	proteomic profiling by mass spectrometry	67	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 283	proteomic profiling by mass spectrometry	67	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 283	proteomic profiling by mass spectrometry	67	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 284	proteomic profiling by mass spectrometry	68	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 284	proteomic profiling by mass spectrometry	68	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 284	proteomic profiling by mass spectrometry	68	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 284	proteomic profiling by mass spectrometry	68	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 284	proteomic profiling by mass spectrometry	68	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 284	proteomic profiling by mass spectrometry	68	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 284	proteomic profiling by mass spectrometry	68	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 284	proteomic profiling by mass spectrometry	68	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 284	proteomic profiling by mass spectrometry	68	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 284	proteomic profiling by mass spectrometry	68	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 285	proteomic profiling by mass spectrometry	69	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 285	proteomic profiling by mass spectrometry	69	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 285	proteomic profiling by mass spectrometry	69	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 285	proteomic profiling by mass spectrometry	69	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 285	proteomic profiling by mass spectrometry	69	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 285	proteomic profiling by mass spectrometry	69	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 285	proteomic profiling by mass spectrometry	69	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 285	proteomic profiling by mass spectrometry	69	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 285	proteomic profiling by mass spectrometry	69	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 285	proteomic profiling by mass spectrometry	69	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 286	proteomic profiling by mass spectrometry	70	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 286	proteomic profiling by mass spectrometry	70	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 286	proteomic profiling by mass spectrometry	70	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 286	proteomic profiling by mass spectrometry	70	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 286	proteomic profiling by mass spectrometry	70	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 286	proteomic profiling by mass spectrometry	70	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 286	proteomic profiling by mass spectrometry	70	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 286	proteomic profiling by mass spectrometry	70	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 286	proteomic profiling by mass spectrometry	70	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 286	proteomic profiling by mass spectrometry	70	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 287	proteomic profiling by mass spectrometry	71	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 287	proteomic profiling by mass spectrometry	71	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 287	proteomic profiling by mass spectrometry	71	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 287	proteomic profiling by mass spectrometry	71	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 287	proteomic profiling by mass spectrometry	71	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 287	proteomic profiling by mass spectrometry	71	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 287	proteomic profiling by mass spectrometry	71	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 287	proteomic profiling by mass spectrometry	71	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 287	proteomic profiling by mass spectrometry	71	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 287	proteomic profiling by mass spectrometry	71	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 31	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_083	tissue	run 288	proteomic profiling by mass spectrometry	72	TMT126	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 32	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_083	tissue	run 288	proteomic profiling by mass spectrometry	72	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 33	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_085	tissue	run 288	proteomic profiling by mass spectrometry	72	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 34	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_085	tissue	run 288	proteomic profiling by mass spectrometry	72	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 35	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_089	tissue	run 288	proteomic profiling by mass spectrometry	72	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 36	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_089	tissue	run 288	proteomic profiling by mass spectrometry	72	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 37	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_092	tissue	run 288	proteomic profiling by mass spectrometry	72	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 38	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_092	tissue	run 288	proteomic profiling by mass spectrometry	72	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 39	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_087	tissue	run 288	proteomic profiling by mass spectrometry	72	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 40	Homo sapiens	blood plasma	4	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS4	tissue	run 288	proteomic profiling by mass spectrometry	72	TMT131	LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set4_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 289	proteomic profiling by mass spectrometry	1	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 289	proteomic profiling by mass spectrometry	1	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 289	proteomic profiling by mass spectrometry	1	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 289	proteomic profiling by mass spectrometry	1	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 289	proteomic profiling by mass spectrometry	1	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 289	proteomic profiling by mass spectrometry	1	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 289	proteomic profiling by mass spectrometry	1	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 289	proteomic profiling by mass spectrometry	1	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 289	proteomic profiling by mass spectrometry	1	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 289	proteomic profiling by mass spectrometry	1	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr01.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 290	proteomic profiling by mass spectrometry	2	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 290	proteomic profiling by mass spectrometry	2	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 290	proteomic profiling by mass spectrometry	2	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 290	proteomic profiling by mass spectrometry	2	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 290	proteomic profiling by mass spectrometry	2	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 290	proteomic profiling by mass spectrometry	2	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 290	proteomic profiling by mass spectrometry	2	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 290	proteomic profiling by mass spectrometry	2	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 290	proteomic profiling by mass spectrometry	2	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 290	proteomic profiling by mass spectrometry	2	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr02.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 291	proteomic profiling by mass spectrometry	3	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 291	proteomic profiling by mass spectrometry	3	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 291	proteomic profiling by mass spectrometry	3	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 291	proteomic profiling by mass spectrometry	3	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 291	proteomic profiling by mass spectrometry	3	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 291	proteomic profiling by mass spectrometry	3	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 291	proteomic profiling by mass spectrometry	3	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 291	proteomic profiling by mass spectrometry	3	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 291	proteomic profiling by mass spectrometry	3	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 291	proteomic profiling by mass spectrometry	3	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr03.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 292	proteomic profiling by mass spectrometry	4	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 292	proteomic profiling by mass spectrometry	4	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 292	proteomic profiling by mass spectrometry	4	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 292	proteomic profiling by mass spectrometry	4	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 292	proteomic profiling by mass spectrometry	4	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 292	proteomic profiling by mass spectrometry	4	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 292	proteomic profiling by mass spectrometry	4	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 292	proteomic profiling by mass spectrometry	4	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 292	proteomic profiling by mass spectrometry	4	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 292	proteomic profiling by mass spectrometry	4	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr04.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 293	proteomic profiling by mass spectrometry	5	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 293	proteomic profiling by mass spectrometry	5	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 293	proteomic profiling by mass spectrometry	5	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 293	proteomic profiling by mass spectrometry	5	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 293	proteomic profiling by mass spectrometry	5	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 293	proteomic profiling by mass spectrometry	5	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 293	proteomic profiling by mass spectrometry	5	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 293	proteomic profiling by mass spectrometry	5	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 293	proteomic profiling by mass spectrometry	5	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 293	proteomic profiling by mass spectrometry	5	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr05.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 294	proteomic profiling by mass spectrometry	6	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 294	proteomic profiling by mass spectrometry	6	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 294	proteomic profiling by mass spectrometry	6	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 294	proteomic profiling by mass spectrometry	6	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 294	proteomic profiling by mass spectrometry	6	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 294	proteomic profiling by mass spectrometry	6	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 294	proteomic profiling by mass spectrometry	6	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 294	proteomic profiling by mass spectrometry	6	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 294	proteomic profiling by mass spectrometry	6	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 294	proteomic profiling by mass spectrometry	6	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr06.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 295	proteomic profiling by mass spectrometry	7	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 295	proteomic profiling by mass spectrometry	7	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 295	proteomic profiling by mass spectrometry	7	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 295	proteomic profiling by mass spectrometry	7	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 295	proteomic profiling by mass spectrometry	7	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 295	proteomic profiling by mass spectrometry	7	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 295	proteomic profiling by mass spectrometry	7	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 295	proteomic profiling by mass spectrometry	7	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 295	proteomic profiling by mass spectrometry	7	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 295	proteomic profiling by mass spectrometry	7	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr07.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 296	proteomic profiling by mass spectrometry	8	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 296	proteomic profiling by mass spectrometry	8	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 296	proteomic profiling by mass spectrometry	8	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 296	proteomic profiling by mass spectrometry	8	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 296	proteomic profiling by mass spectrometry	8	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 296	proteomic profiling by mass spectrometry	8	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 296	proteomic profiling by mass spectrometry	8	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 296	proteomic profiling by mass spectrometry	8	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 296	proteomic profiling by mass spectrometry	8	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 296	proteomic profiling by mass spectrometry	8	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr08.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 297	proteomic profiling by mass spectrometry	9	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 297	proteomic profiling by mass spectrometry	9	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 297	proteomic profiling by mass spectrometry	9	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 297	proteomic profiling by mass spectrometry	9	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 297	proteomic profiling by mass spectrometry	9	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 297	proteomic profiling by mass spectrometry	9	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 297	proteomic profiling by mass spectrometry	9	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 297	proteomic profiling by mass spectrometry	9	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 297	proteomic profiling by mass spectrometry	9	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 297	proteomic profiling by mass spectrometry	9	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr09.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 298	proteomic profiling by mass spectrometry	10	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 298	proteomic profiling by mass spectrometry	10	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 298	proteomic profiling by mass spectrometry	10	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 298	proteomic profiling by mass spectrometry	10	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 298	proteomic profiling by mass spectrometry	10	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 298	proteomic profiling by mass spectrometry	10	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 298	proteomic profiling by mass spectrometry	10	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 298	proteomic profiling by mass spectrometry	10	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 298	proteomic profiling by mass spectrometry	10	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 298	proteomic profiling by mass spectrometry	10	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr10.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 299	proteomic profiling by mass spectrometry	11	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 299	proteomic profiling by mass spectrometry	11	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 299	proteomic profiling by mass spectrometry	11	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 299	proteomic profiling by mass spectrometry	11	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 299	proteomic profiling by mass spectrometry	11	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 299	proteomic profiling by mass spectrometry	11	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 299	proteomic profiling by mass spectrometry	11	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 299	proteomic profiling by mass spectrometry	11	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 299	proteomic profiling by mass spectrometry	11	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 299	proteomic profiling by mass spectrometry	11	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr11.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 300	proteomic profiling by mass spectrometry	12	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 300	proteomic profiling by mass spectrometry	12	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 300	proteomic profiling by mass spectrometry	12	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 300	proteomic profiling by mass spectrometry	12	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 300	proteomic profiling by mass spectrometry	12	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 300	proteomic profiling by mass spectrometry	12	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 300	proteomic profiling by mass spectrometry	12	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 300	proteomic profiling by mass spectrometry	12	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 300	proteomic profiling by mass spectrometry	12	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 300	proteomic profiling by mass spectrometry	12	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr12.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 301	proteomic profiling by mass spectrometry	13	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 301	proteomic profiling by mass spectrometry	13	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 301	proteomic profiling by mass spectrometry	13	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 301	proteomic profiling by mass spectrometry	13	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 301	proteomic profiling by mass spectrometry	13	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 301	proteomic profiling by mass spectrometry	13	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 301	proteomic profiling by mass spectrometry	13	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 301	proteomic profiling by mass spectrometry	13	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 301	proteomic profiling by mass spectrometry	13	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 301	proteomic profiling by mass spectrometry	13	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr13.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 302	proteomic profiling by mass spectrometry	14	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 302	proteomic profiling by mass spectrometry	14	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 302	proteomic profiling by mass spectrometry	14	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 302	proteomic profiling by mass spectrometry	14	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 302	proteomic profiling by mass spectrometry	14	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 302	proteomic profiling by mass spectrometry	14	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 302	proteomic profiling by mass spectrometry	14	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 302	proteomic profiling by mass spectrometry	14	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 302	proteomic profiling by mass spectrometry	14	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 302	proteomic profiling by mass spectrometry	14	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr14.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 303	proteomic profiling by mass spectrometry	15	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 303	proteomic profiling by mass spectrometry	15	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 303	proteomic profiling by mass spectrometry	15	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 303	proteomic profiling by mass spectrometry	15	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 303	proteomic profiling by mass spectrometry	15	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 303	proteomic profiling by mass spectrometry	15	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 303	proteomic profiling by mass spectrometry	15	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 303	proteomic profiling by mass spectrometry	15	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 303	proteomic profiling by mass spectrometry	15	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 303	proteomic profiling by mass spectrometry	15	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr15.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 304	proteomic profiling by mass spectrometry	16	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 304	proteomic profiling by mass spectrometry	16	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 304	proteomic profiling by mass spectrometry	16	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 304	proteomic profiling by mass spectrometry	16	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 304	proteomic profiling by mass spectrometry	16	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 304	proteomic profiling by mass spectrometry	16	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 304	proteomic profiling by mass spectrometry	16	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 304	proteomic profiling by mass spectrometry	16	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 304	proteomic profiling by mass spectrometry	16	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 304	proteomic profiling by mass spectrometry	16	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr16.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 305	proteomic profiling by mass spectrometry	17	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 305	proteomic profiling by mass spectrometry	17	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 305	proteomic profiling by mass spectrometry	17	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 305	proteomic profiling by mass spectrometry	17	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 305	proteomic profiling by mass spectrometry	17	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 305	proteomic profiling by mass spectrometry	17	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 305	proteomic profiling by mass spectrometry	17	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 305	proteomic profiling by mass spectrometry	17	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 305	proteomic profiling by mass spectrometry	17	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 305	proteomic profiling by mass spectrometry	17	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr17.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 306	proteomic profiling by mass spectrometry	18	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 306	proteomic profiling by mass spectrometry	18	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 306	proteomic profiling by mass spectrometry	18	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 306	proteomic profiling by mass spectrometry	18	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 306	proteomic profiling by mass spectrometry	18	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 306	proteomic profiling by mass spectrometry	18	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 306	proteomic profiling by mass spectrometry	18	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 306	proteomic profiling by mass spectrometry	18	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 306	proteomic profiling by mass spectrometry	18	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 306	proteomic profiling by mass spectrometry	18	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr18.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 307	proteomic profiling by mass spectrometry	19	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 307	proteomic profiling by mass spectrometry	19	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 307	proteomic profiling by mass spectrometry	19	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 307	proteomic profiling by mass spectrometry	19	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 307	proteomic profiling by mass spectrometry	19	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 307	proteomic profiling by mass spectrometry	19	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 307	proteomic profiling by mass spectrometry	19	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 307	proteomic profiling by mass spectrometry	19	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 307	proteomic profiling by mass spectrometry	19	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 307	proteomic profiling by mass spectrometry	19	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr19.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 308	proteomic profiling by mass spectrometry	20	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 308	proteomic profiling by mass spectrometry	20	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 308	proteomic profiling by mass spectrometry	20	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 308	proteomic profiling by mass spectrometry	20	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 308	proteomic profiling by mass spectrometry	20	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 308	proteomic profiling by mass spectrometry	20	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 308	proteomic profiling by mass spectrometry	20	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 308	proteomic profiling by mass spectrometry	20	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 308	proteomic profiling by mass spectrometry	20	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 308	proteomic profiling by mass spectrometry	20	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr20.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 309	proteomic profiling by mass spectrometry	21	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 309	proteomic profiling by mass spectrometry	21	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 309	proteomic profiling by mass spectrometry	21	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 309	proteomic profiling by mass spectrometry	21	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 309	proteomic profiling by mass spectrometry	21	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 309	proteomic profiling by mass spectrometry	21	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 309	proteomic profiling by mass spectrometry	21	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 309	proteomic profiling by mass spectrometry	21	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 309	proteomic profiling by mass spectrometry	21	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 309	proteomic profiling by mass spectrometry	21	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr21.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 310	proteomic profiling by mass spectrometry	22	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 310	proteomic profiling by mass spectrometry	22	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 310	proteomic profiling by mass spectrometry	22	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 310	proteomic profiling by mass spectrometry	22	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 310	proteomic profiling by mass spectrometry	22	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 310	proteomic profiling by mass spectrometry	22	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 310	proteomic profiling by mass spectrometry	22	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 310	proteomic profiling by mass spectrometry	22	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 310	proteomic profiling by mass spectrometry	22	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 310	proteomic profiling by mass spectrometry	22	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr22.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 311	proteomic profiling by mass spectrometry	23	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 311	proteomic profiling by mass spectrometry	23	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 311	proteomic profiling by mass spectrometry	23	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 311	proteomic profiling by mass spectrometry	23	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 311	proteomic profiling by mass spectrometry	23	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 311	proteomic profiling by mass spectrometry	23	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 311	proteomic profiling by mass spectrometry	23	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 311	proteomic profiling by mass spectrometry	23	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 311	proteomic profiling by mass spectrometry	23	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 311	proteomic profiling by mass spectrometry	23	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr23.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 312	proteomic profiling by mass spectrometry	24	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 312	proteomic profiling by mass spectrometry	24	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 312	proteomic profiling by mass spectrometry	24	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 312	proteomic profiling by mass spectrometry	24	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 312	proteomic profiling by mass spectrometry	24	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 312	proteomic profiling by mass spectrometry	24	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 312	proteomic profiling by mass spectrometry	24	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 312	proteomic profiling by mass spectrometry	24	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 312	proteomic profiling by mass spectrometry	24	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 312	proteomic profiling by mass spectrometry	24	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr24.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 313	proteomic profiling by mass spectrometry	25	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 313	proteomic profiling by mass spectrometry	25	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 313	proteomic profiling by mass spectrometry	25	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 313	proteomic profiling by mass spectrometry	25	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 313	proteomic profiling by mass spectrometry	25	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 313	proteomic profiling by mass spectrometry	25	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 313	proteomic profiling by mass spectrometry	25	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 313	proteomic profiling by mass spectrometry	25	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 313	proteomic profiling by mass spectrometry	25	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 313	proteomic profiling by mass spectrometry	25	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr25.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 314	proteomic profiling by mass spectrometry	26	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 314	proteomic profiling by mass spectrometry	26	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 314	proteomic profiling by mass spectrometry	26	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 314	proteomic profiling by mass spectrometry	26	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 314	proteomic profiling by mass spectrometry	26	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 314	proteomic profiling by mass spectrometry	26	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 314	proteomic profiling by mass spectrometry	26	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 314	proteomic profiling by mass spectrometry	26	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 314	proteomic profiling by mass spectrometry	26	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 314	proteomic profiling by mass spectrometry	26	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr26.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 315	proteomic profiling by mass spectrometry	27	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 315	proteomic profiling by mass spectrometry	27	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 315	proteomic profiling by mass spectrometry	27	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 315	proteomic profiling by mass spectrometry	27	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 315	proteomic profiling by mass spectrometry	27	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 315	proteomic profiling by mass spectrometry	27	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 315	proteomic profiling by mass spectrometry	27	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 315	proteomic profiling by mass spectrometry	27	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 315	proteomic profiling by mass spectrometry	27	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 315	proteomic profiling by mass spectrometry	27	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr27.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 316	proteomic profiling by mass spectrometry	28	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 316	proteomic profiling by mass spectrometry	28	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 316	proteomic profiling by mass spectrometry	28	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 316	proteomic profiling by mass spectrometry	28	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 316	proteomic profiling by mass spectrometry	28	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 316	proteomic profiling by mass spectrometry	28	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 316	proteomic profiling by mass spectrometry	28	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 316	proteomic profiling by mass spectrometry	28	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 316	proteomic profiling by mass spectrometry	28	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 316	proteomic profiling by mass spectrometry	28	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr28.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 317	proteomic profiling by mass spectrometry	29	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 317	proteomic profiling by mass spectrometry	29	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 317	proteomic profiling by mass spectrometry	29	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 317	proteomic profiling by mass spectrometry	29	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 317	proteomic profiling by mass spectrometry	29	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 317	proteomic profiling by mass spectrometry	29	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 317	proteomic profiling by mass spectrometry	29	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 317	proteomic profiling by mass spectrometry	29	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 317	proteomic profiling by mass spectrometry	29	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 317	proteomic profiling by mass spectrometry	29	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr29.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 318	proteomic profiling by mass spectrometry	30	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 318	proteomic profiling by mass spectrometry	30	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 318	proteomic profiling by mass spectrometry	30	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 318	proteomic profiling by mass spectrometry	30	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 318	proteomic profiling by mass spectrometry	30	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 318	proteomic profiling by mass spectrometry	30	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 318	proteomic profiling by mass spectrometry	30	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 318	proteomic profiling by mass spectrometry	30	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 318	proteomic profiling by mass spectrometry	30	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 318	proteomic profiling by mass spectrometry	30	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr30.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 319	proteomic profiling by mass spectrometry	31	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 319	proteomic profiling by mass spectrometry	31	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 319	proteomic profiling by mass spectrometry	31	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 319	proteomic profiling by mass spectrometry	31	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 319	proteomic profiling by mass spectrometry	31	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 319	proteomic profiling by mass spectrometry	31	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 319	proteomic profiling by mass spectrometry	31	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 319	proteomic profiling by mass spectrometry	31	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 319	proteomic profiling by mass spectrometry	31	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 319	proteomic profiling by mass spectrometry	31	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr31.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 320	proteomic profiling by mass spectrometry	32	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 320	proteomic profiling by mass spectrometry	32	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 320	proteomic profiling by mass spectrometry	32	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 320	proteomic profiling by mass spectrometry	32	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 320	proteomic profiling by mass spectrometry	32	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 320	proteomic profiling by mass spectrometry	32	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 320	proteomic profiling by mass spectrometry	32	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 320	proteomic profiling by mass spectrometry	32	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 320	proteomic profiling by mass spectrometry	32	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 320	proteomic profiling by mass spectrometry	32	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr32.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 321	proteomic profiling by mass spectrometry	33	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 321	proteomic profiling by mass spectrometry	33	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 321	proteomic profiling by mass spectrometry	33	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 321	proteomic profiling by mass spectrometry	33	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 321	proteomic profiling by mass spectrometry	33	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 321	proteomic profiling by mass spectrometry	33	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 321	proteomic profiling by mass spectrometry	33	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 321	proteomic profiling by mass spectrometry	33	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 321	proteomic profiling by mass spectrometry	33	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 321	proteomic profiling by mass spectrometry	33	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr33.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 322	proteomic profiling by mass spectrometry	34	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 322	proteomic profiling by mass spectrometry	34	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 322	proteomic profiling by mass spectrometry	34	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 322	proteomic profiling by mass spectrometry	34	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 322	proteomic profiling by mass spectrometry	34	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 322	proteomic profiling by mass spectrometry	34	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 322	proteomic profiling by mass spectrometry	34	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 322	proteomic profiling by mass spectrometry	34	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 322	proteomic profiling by mass spectrometry	34	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 322	proteomic profiling by mass spectrometry	34	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr34.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 323	proteomic profiling by mass spectrometry	35	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 323	proteomic profiling by mass spectrometry	35	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 323	proteomic profiling by mass spectrometry	35	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 323	proteomic profiling by mass spectrometry	35	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 323	proteomic profiling by mass spectrometry	35	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 323	proteomic profiling by mass spectrometry	35	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 323	proteomic profiling by mass spectrometry	35	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 323	proteomic profiling by mass spectrometry	35	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 323	proteomic profiling by mass spectrometry	35	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 323	proteomic profiling by mass spectrometry	35	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr35.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 324	proteomic profiling by mass spectrometry	36	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 324	proteomic profiling by mass spectrometry	36	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 324	proteomic profiling by mass spectrometry	36	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 324	proteomic profiling by mass spectrometry	36	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 324	proteomic profiling by mass spectrometry	36	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 324	proteomic profiling by mass spectrometry	36	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 324	proteomic profiling by mass spectrometry	36	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 324	proteomic profiling by mass spectrometry	36	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 324	proteomic profiling by mass spectrometry	36	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 324	proteomic profiling by mass spectrometry	36	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr36.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 325	proteomic profiling by mass spectrometry	37	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 325	proteomic profiling by mass spectrometry	37	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 325	proteomic profiling by mass spectrometry	37	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 325	proteomic profiling by mass spectrometry	37	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 325	proteomic profiling by mass spectrometry	37	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 325	proteomic profiling by mass spectrometry	37	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 325	proteomic profiling by mass spectrometry	37	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 325	proteomic profiling by mass spectrometry	37	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 325	proteomic profiling by mass spectrometry	37	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 325	proteomic profiling by mass spectrometry	37	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr37.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 326	proteomic profiling by mass spectrometry	38	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 326	proteomic profiling by mass spectrometry	38	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 326	proteomic profiling by mass spectrometry	38	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 326	proteomic profiling by mass spectrometry	38	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 326	proteomic profiling by mass spectrometry	38	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 326	proteomic profiling by mass spectrometry	38	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 326	proteomic profiling by mass spectrometry	38	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 326	proteomic profiling by mass spectrometry	38	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 326	proteomic profiling by mass spectrometry	38	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 326	proteomic profiling by mass spectrometry	38	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr38.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 327	proteomic profiling by mass spectrometry	39	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 327	proteomic profiling by mass spectrometry	39	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 327	proteomic profiling by mass spectrometry	39	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 327	proteomic profiling by mass spectrometry	39	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 327	proteomic profiling by mass spectrometry	39	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 327	proteomic profiling by mass spectrometry	39	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 327	proteomic profiling by mass spectrometry	39	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 327	proteomic profiling by mass spectrometry	39	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 327	proteomic profiling by mass spectrometry	39	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 327	proteomic profiling by mass spectrometry	39	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr39.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 328	proteomic profiling by mass spectrometry	40	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 328	proteomic profiling by mass spectrometry	40	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 328	proteomic profiling by mass spectrometry	40	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 328	proteomic profiling by mass spectrometry	40	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 328	proteomic profiling by mass spectrometry	40	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 328	proteomic profiling by mass spectrometry	40	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 328	proteomic profiling by mass spectrometry	40	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 328	proteomic profiling by mass spectrometry	40	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 328	proteomic profiling by mass spectrometry	40	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 328	proteomic profiling by mass spectrometry	40	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr40.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 329	proteomic profiling by mass spectrometry	41	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 329	proteomic profiling by mass spectrometry	41	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 329	proteomic profiling by mass spectrometry	41	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 329	proteomic profiling by mass spectrometry	41	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 329	proteomic profiling by mass spectrometry	41	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 329	proteomic profiling by mass spectrometry	41	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 329	proteomic profiling by mass spectrometry	41	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 329	proteomic profiling by mass spectrometry	41	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 329	proteomic profiling by mass spectrometry	41	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 329	proteomic profiling by mass spectrometry	41	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr41.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 330	proteomic profiling by mass spectrometry	42	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 330	proteomic profiling by mass spectrometry	42	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 330	proteomic profiling by mass spectrometry	42	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 330	proteomic profiling by mass spectrometry	42	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 330	proteomic profiling by mass spectrometry	42	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 330	proteomic profiling by mass spectrometry	42	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 330	proteomic profiling by mass spectrometry	42	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 330	proteomic profiling by mass spectrometry	42	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 330	proteomic profiling by mass spectrometry	42	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 330	proteomic profiling by mass spectrometry	42	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr42.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 331	proteomic profiling by mass spectrometry	43	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 331	proteomic profiling by mass spectrometry	43	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 331	proteomic profiling by mass spectrometry	43	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 331	proteomic profiling by mass spectrometry	43	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 331	proteomic profiling by mass spectrometry	43	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 331	proteomic profiling by mass spectrometry	43	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 331	proteomic profiling by mass spectrometry	43	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 331	proteomic profiling by mass spectrometry	43	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 331	proteomic profiling by mass spectrometry	43	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 331	proteomic profiling by mass spectrometry	43	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr43.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 332	proteomic profiling by mass spectrometry	44	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 332	proteomic profiling by mass spectrometry	44	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 332	proteomic profiling by mass spectrometry	44	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 332	proteomic profiling by mass spectrometry	44	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 332	proteomic profiling by mass spectrometry	44	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 332	proteomic profiling by mass spectrometry	44	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 332	proteomic profiling by mass spectrometry	44	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 332	proteomic profiling by mass spectrometry	44	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 332	proteomic profiling by mass spectrometry	44	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 332	proteomic profiling by mass spectrometry	44	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr44.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 333	proteomic profiling by mass spectrometry	45	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 333	proteomic profiling by mass spectrometry	45	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 333	proteomic profiling by mass spectrometry	45	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 333	proteomic profiling by mass spectrometry	45	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 333	proteomic profiling by mass spectrometry	45	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 333	proteomic profiling by mass spectrometry	45	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 333	proteomic profiling by mass spectrometry	45	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 333	proteomic profiling by mass spectrometry	45	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 333	proteomic profiling by mass spectrometry	45	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 333	proteomic profiling by mass spectrometry	45	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr45.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 334	proteomic profiling by mass spectrometry	46	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 334	proteomic profiling by mass spectrometry	46	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 334	proteomic profiling by mass spectrometry	46	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 334	proteomic profiling by mass spectrometry	46	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 334	proteomic profiling by mass spectrometry	46	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 334	proteomic profiling by mass spectrometry	46	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 334	proteomic profiling by mass spectrometry	46	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 334	proteomic profiling by mass spectrometry	46	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 334	proteomic profiling by mass spectrometry	46	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 334	proteomic profiling by mass spectrometry	46	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr46.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 335	proteomic profiling by mass spectrometry	47	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 335	proteomic profiling by mass spectrometry	47	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 335	proteomic profiling by mass spectrometry	47	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 335	proteomic profiling by mass spectrometry	47	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 335	proteomic profiling by mass spectrometry	47	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 335	proteomic profiling by mass spectrometry	47	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 335	proteomic profiling by mass spectrometry	47	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 335	proteomic profiling by mass spectrometry	47	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 335	proteomic profiling by mass spectrometry	47	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 335	proteomic profiling by mass spectrometry	47	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr47.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 336	proteomic profiling by mass spectrometry	48	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 336	proteomic profiling by mass spectrometry	48	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 336	proteomic profiling by mass spectrometry	48	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 336	proteomic profiling by mass spectrometry	48	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 336	proteomic profiling by mass spectrometry	48	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 336	proteomic profiling by mass spectrometry	48	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 336	proteomic profiling by mass spectrometry	48	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 336	proteomic profiling by mass spectrometry	48	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 336	proteomic profiling by mass spectrometry	48	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 336	proteomic profiling by mass spectrometry	48	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr48.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 337	proteomic profiling by mass spectrometry	49	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 337	proteomic profiling by mass spectrometry	49	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 337	proteomic profiling by mass spectrometry	49	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 337	proteomic profiling by mass spectrometry	49	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 337	proteomic profiling by mass spectrometry	49	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 337	proteomic profiling by mass spectrometry	49	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 337	proteomic profiling by mass spectrometry	49	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 337	proteomic profiling by mass spectrometry	49	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 337	proteomic profiling by mass spectrometry	49	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 337	proteomic profiling by mass spectrometry	49	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr49.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 338	proteomic profiling by mass spectrometry	50	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 338	proteomic profiling by mass spectrometry	50	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 338	proteomic profiling by mass spectrometry	50	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 338	proteomic profiling by mass spectrometry	50	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 338	proteomic profiling by mass spectrometry	50	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 338	proteomic profiling by mass spectrometry	50	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 338	proteomic profiling by mass spectrometry	50	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 338	proteomic profiling by mass spectrometry	50	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 338	proteomic profiling by mass spectrometry	50	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 338	proteomic profiling by mass spectrometry	50	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr50.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 339	proteomic profiling by mass spectrometry	51	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 339	proteomic profiling by mass spectrometry	51	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 339	proteomic profiling by mass spectrometry	51	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 339	proteomic profiling by mass spectrometry	51	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 339	proteomic profiling by mass spectrometry	51	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 339	proteomic profiling by mass spectrometry	51	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 339	proteomic profiling by mass spectrometry	51	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 339	proteomic profiling by mass spectrometry	51	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 339	proteomic profiling by mass spectrometry	51	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 339	proteomic profiling by mass spectrometry	51	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr51.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 340	proteomic profiling by mass spectrometry	52	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 340	proteomic profiling by mass spectrometry	52	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 340	proteomic profiling by mass spectrometry	52	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 340	proteomic profiling by mass spectrometry	52	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 340	proteomic profiling by mass spectrometry	52	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 340	proteomic profiling by mass spectrometry	52	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 340	proteomic profiling by mass spectrometry	52	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 340	proteomic profiling by mass spectrometry	52	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 340	proteomic profiling by mass spectrometry	52	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 340	proteomic profiling by mass spectrometry	52	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr52.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 341	proteomic profiling by mass spectrometry	53	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 341	proteomic profiling by mass spectrometry	53	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 341	proteomic profiling by mass spectrometry	53	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 341	proteomic profiling by mass spectrometry	53	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 341	proteomic profiling by mass spectrometry	53	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 341	proteomic profiling by mass spectrometry	53	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 341	proteomic profiling by mass spectrometry	53	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 341	proteomic profiling by mass spectrometry	53	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 341	proteomic profiling by mass spectrometry	53	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 341	proteomic profiling by mass spectrometry	53	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr53.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 342	proteomic profiling by mass spectrometry	54	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 342	proteomic profiling by mass spectrometry	54	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 342	proteomic profiling by mass spectrometry	54	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 342	proteomic profiling by mass spectrometry	54	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 342	proteomic profiling by mass spectrometry	54	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 342	proteomic profiling by mass spectrometry	54	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 342	proteomic profiling by mass spectrometry	54	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 342	proteomic profiling by mass spectrometry	54	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 342	proteomic profiling by mass spectrometry	54	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 342	proteomic profiling by mass spectrometry	54	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr54.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 343	proteomic profiling by mass spectrometry	55	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 343	proteomic profiling by mass spectrometry	55	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 343	proteomic profiling by mass spectrometry	55	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 343	proteomic profiling by mass spectrometry	55	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 343	proteomic profiling by mass spectrometry	55	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 343	proteomic profiling by mass spectrometry	55	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 343	proteomic profiling by mass spectrometry	55	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 343	proteomic profiling by mass spectrometry	55	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 343	proteomic profiling by mass spectrometry	55	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 343	proteomic profiling by mass spectrometry	55	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr55.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 344	proteomic profiling by mass spectrometry	56	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 344	proteomic profiling by mass spectrometry	56	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 344	proteomic profiling by mass spectrometry	56	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 344	proteomic profiling by mass spectrometry	56	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 344	proteomic profiling by mass spectrometry	56	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 344	proteomic profiling by mass spectrometry	56	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 344	proteomic profiling by mass spectrometry	56	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 344	proteomic profiling by mass spectrometry	56	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 344	proteomic profiling by mass spectrometry	56	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 344	proteomic profiling by mass spectrometry	56	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr56.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 345	proteomic profiling by mass spectrometry	57	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 345	proteomic profiling by mass spectrometry	57	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 345	proteomic profiling by mass spectrometry	57	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 345	proteomic profiling by mass spectrometry	57	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 345	proteomic profiling by mass spectrometry	57	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 345	proteomic profiling by mass spectrometry	57	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 345	proteomic profiling by mass spectrometry	57	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 345	proteomic profiling by mass spectrometry	57	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 345	proteomic profiling by mass spectrometry	57	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 345	proteomic profiling by mass spectrometry	57	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr57.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 346	proteomic profiling by mass spectrometry	58	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 346	proteomic profiling by mass spectrometry	58	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 346	proteomic profiling by mass spectrometry	58	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 346	proteomic profiling by mass spectrometry	58	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 346	proteomic profiling by mass spectrometry	58	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 346	proteomic profiling by mass spectrometry	58	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 346	proteomic profiling by mass spectrometry	58	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 346	proteomic profiling by mass spectrometry	58	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 346	proteomic profiling by mass spectrometry	58	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 346	proteomic profiling by mass spectrometry	58	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr58.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 347	proteomic profiling by mass spectrometry	59	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 347	proteomic profiling by mass spectrometry	59	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 347	proteomic profiling by mass spectrometry	59	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 347	proteomic profiling by mass spectrometry	59	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 347	proteomic profiling by mass spectrometry	59	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 347	proteomic profiling by mass spectrometry	59	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 347	proteomic profiling by mass spectrometry	59	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 347	proteomic profiling by mass spectrometry	59	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 347	proteomic profiling by mass spectrometry	59	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 347	proteomic profiling by mass spectrometry	59	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr59.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 348	proteomic profiling by mass spectrometry	60	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 348	proteomic profiling by mass spectrometry	60	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 348	proteomic profiling by mass spectrometry	60	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 348	proteomic profiling by mass spectrometry	60	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 348	proteomic profiling by mass spectrometry	60	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 348	proteomic profiling by mass spectrometry	60	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 348	proteomic profiling by mass spectrometry	60	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 348	proteomic profiling by mass spectrometry	60	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 348	proteomic profiling by mass spectrometry	60	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 348	proteomic profiling by mass spectrometry	60	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr60.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 349	proteomic profiling by mass spectrometry	61	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 349	proteomic profiling by mass spectrometry	61	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 349	proteomic profiling by mass spectrometry	61	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 349	proteomic profiling by mass spectrometry	61	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 349	proteomic profiling by mass spectrometry	61	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 349	proteomic profiling by mass spectrometry	61	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 349	proteomic profiling by mass spectrometry	61	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 349	proteomic profiling by mass spectrometry	61	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 349	proteomic profiling by mass spectrometry	61	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 349	proteomic profiling by mass spectrometry	61	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr61.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 350	proteomic profiling by mass spectrometry	62	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 350	proteomic profiling by mass spectrometry	62	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 350	proteomic profiling by mass spectrometry	62	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 350	proteomic profiling by mass spectrometry	62	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 350	proteomic profiling by mass spectrometry	62	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 350	proteomic profiling by mass spectrometry	62	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 350	proteomic profiling by mass spectrometry	62	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 350	proteomic profiling by mass spectrometry	62	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 350	proteomic profiling by mass spectrometry	62	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 350	proteomic profiling by mass spectrometry	62	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr62.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 351	proteomic profiling by mass spectrometry	63	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 351	proteomic profiling by mass spectrometry	63	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 351	proteomic profiling by mass spectrometry	63	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 351	proteomic profiling by mass spectrometry	63	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 351	proteomic profiling by mass spectrometry	63	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 351	proteomic profiling by mass spectrometry	63	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 351	proteomic profiling by mass spectrometry	63	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 351	proteomic profiling by mass spectrometry	63	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 351	proteomic profiling by mass spectrometry	63	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 351	proteomic profiling by mass spectrometry	63	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr63.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 352	proteomic profiling by mass spectrometry	64	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 352	proteomic profiling by mass spectrometry	64	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 352	proteomic profiling by mass spectrometry	64	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 352	proteomic profiling by mass spectrometry	64	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 352	proteomic profiling by mass spectrometry	64	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 352	proteomic profiling by mass spectrometry	64	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 352	proteomic profiling by mass spectrometry	64	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 352	proteomic profiling by mass spectrometry	64	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 352	proteomic profiling by mass spectrometry	64	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 352	proteomic profiling by mass spectrometry	64	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr64.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 353	proteomic profiling by mass spectrometry	65	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 353	proteomic profiling by mass spectrometry	65	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 353	proteomic profiling by mass spectrometry	65	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 353	proteomic profiling by mass spectrometry	65	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 353	proteomic profiling by mass spectrometry	65	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 353	proteomic profiling by mass spectrometry	65	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 353	proteomic profiling by mass spectrometry	65	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 353	proteomic profiling by mass spectrometry	65	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 353	proteomic profiling by mass spectrometry	65	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 353	proteomic profiling by mass spectrometry	65	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr65.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 354	proteomic profiling by mass spectrometry	66	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 354	proteomic profiling by mass spectrometry	66	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 354	proteomic profiling by mass spectrometry	66	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 354	proteomic profiling by mass spectrometry	66	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 354	proteomic profiling by mass spectrometry	66	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 354	proteomic profiling by mass spectrometry	66	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 354	proteomic profiling by mass spectrometry	66	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 354	proteomic profiling by mass spectrometry	66	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 354	proteomic profiling by mass spectrometry	66	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 354	proteomic profiling by mass spectrometry	66	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr66.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 355	proteomic profiling by mass spectrometry	67	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 355	proteomic profiling by mass spectrometry	67	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 355	proteomic profiling by mass spectrometry	67	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 355	proteomic profiling by mass spectrometry	67	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 355	proteomic profiling by mass spectrometry	67	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 355	proteomic profiling by mass spectrometry	67	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 355	proteomic profiling by mass spectrometry	67	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 355	proteomic profiling by mass spectrometry	67	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 355	proteomic profiling by mass spectrometry	67	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 355	proteomic profiling by mass spectrometry	67	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr67.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 356	proteomic profiling by mass spectrometry	68	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 356	proteomic profiling by mass spectrometry	68	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 356	proteomic profiling by mass spectrometry	68	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 356	proteomic profiling by mass spectrometry	68	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 356	proteomic profiling by mass spectrometry	68	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 356	proteomic profiling by mass spectrometry	68	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 356	proteomic profiling by mass spectrometry	68	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 356	proteomic profiling by mass spectrometry	68	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 356	proteomic profiling by mass spectrometry	68	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 356	proteomic profiling by mass spectrometry	68	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr68.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 357	proteomic profiling by mass spectrometry	69	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 357	proteomic profiling by mass spectrometry	69	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 357	proteomic profiling by mass spectrometry	69	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 357	proteomic profiling by mass spectrometry	69	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 357	proteomic profiling by mass spectrometry	69	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 357	proteomic profiling by mass spectrometry	69	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 357	proteomic profiling by mass spectrometry	69	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 357	proteomic profiling by mass spectrometry	69	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 357	proteomic profiling by mass spectrometry	69	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 357	proteomic profiling by mass spectrometry	69	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr69.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 358	proteomic profiling by mass spectrometry	70	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 358	proteomic profiling by mass spectrometry	70	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 358	proteomic profiling by mass spectrometry	70	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 358	proteomic profiling by mass spectrometry	70	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 358	proteomic profiling by mass spectrometry	70	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 358	proteomic profiling by mass spectrometry	70	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 358	proteomic profiling by mass spectrometry	70	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 358	proteomic profiling by mass spectrometry	70	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 358	proteomic profiling by mass spectrometry	70	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 358	proteomic profiling by mass spectrometry	70	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr70.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 359	proteomic profiling by mass spectrometry	71	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 359	proteomic profiling by mass spectrometry	71	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 359	proteomic profiling by mass spectrometry	71	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 359	proteomic profiling by mass spectrometry	71	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 359	proteomic profiling by mass spectrometry	71	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 359	proteomic profiling by mass spectrometry	71	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 359	proteomic profiling by mass spectrometry	71	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 359	proteomic profiling by mass spectrometry	71	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 359	proteomic profiling by mass spectrometry	71	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 359	proteomic profiling by mass spectrometry	71	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr71.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
Sample 41	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_087	tissue	run 360	proteomic profiling by mass spectrometry	72	TMT126	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 42	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_088	tissue	run 360	proteomic profiling by mass spectrometry	72	TMT127N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 43	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_088	tissue	run 360	proteomic profiling by mass spectrometry	72	TMT127C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 44	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_093	tissue	run 360	proteomic profiling by mass spectrometry	72	TMT128N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 45	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_093	tissue	run 360	proteomic profiling by mass spectrometry	72	TMT128C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 46	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_096	tissue	run 360	proteomic profiling by mass spectrometry	72	TMT129N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	before_treatment
Sample 47	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug MAPK-inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_096	tissue	run 360	proteomic profiling by mass spectrometry	72	TMT129C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug MAPK-inhibitors	treatment
Sample 48	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	before_treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	pre_100	tissue	run 360	proteomic profiling by mass spectrometry	72	TMT130N	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	before_treatment
Sample 49	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	drug immune checkpoint inhibitors	treatment	depletion	not applicable	not available	metastatic cutaneous melanoma	trm_100	tissue	run 360	proteomic profiling by mass spectrometry	72	TMT130C	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	drug immune checkpoint inhibitors	treatment
Sample 50	Homo sapiens	blood plasma	5	not available	not available	not applicable	not available	control	control	depletion	not applicable	not available	metastatic cutaneous melanoma	IS5	tissue	run 360	proteomic profiling by mass spectrometry	72	TMT131	LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017201/LJMP_Melanoma_QE_20170310_TMT_set5_1mgIPG3-10_fr72.raw	NT=Q Exactive;AC=MS:1001911	NT=Trypsin;AC=MS:1001251	NT=Oxidation;TA=M;AC=UNIMOD:35;MT=variable	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;PP=Protein N-term	NT=TMT6plex;AC=UNIMOD:737;MT=fixed;TA=K	AC=MS:1000422;NT=HCD	30% NCE	not available	not available	control	control
